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by 
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 ABSTRACT 
Background: Recent estimates suggest that 7% of Americans use plant-derived nutritional 
supplements to treat a variety of complications and/or to improve athletic performance and 
skeletal muscle health.  Unfortunately, these supplements are largely unregulated and 
understudied.  For example, Moringa oleifera (M. oleifera) is a subtropical plant and is routinely 
used to treat inflammation, diabetes, obesity, cancer and HIV.  However, the mechanism of 
action of M. oleifera has not been fully elucidated, thus the purpose of this study is to evaluate 
the role of M. oleifera as a novel ergogenic aid to improve exercise performance by driving 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α)-dependent 
signaling pathways implicated in mitochondrial biogenesis and oxidative metabolism in skeletal 
muscle tissue.  Methods: Adult male C57BL/6 mice were treated with 1.0 g of M. oleifera (N = 
20) per day or vehicle control (N = 20) for a total of 5 weeks.  Following 3 weeks of 
supplementation, half of each group (RUN) was given access to running wheels every night for 2 
weeks (Remaining half = SED), distances ran were recorded daily.  After treatment protocols 
were complete, the gastrocnemius muscles were excised and assayed for known markers of 
mitochondrial biogenesis, angiogenesis, endurance capacity, and capillary density using 
immunohistochemistry and RT-PCR.  Results: Our results showed a significant increase in 
average distance run in the M. oleifera + SED and M. oleifera + RUN groups.  This 
physiological trend was consistent with the molecular profile of key metabolic markers, i.e., 
there was an increase in levels of PGC-1α, PPARγ, SDHB, SUCLG1, VEGF, PGAM-2, PGK1, 
and MYLPF in the M. oleifera treated groups compared to vehicle + SED.  Moreover, M. 
oleifera also increased CSA and decreased markers of protein degradation. Conclusions: This 
data suggests that M. oleifera has the potential to be an ergogenic aid via enhancing energy 
 metabolism in adult skeletal muscle by increasing the expression of key metabolic markers, 
including those involved in glycolysis, oxidative phosphorylation, mitochondrial biogenesis and 
angiogenesis.     
INDEX WORDS: ergogenic aid, PGC-1α, Moringa oleifera, mitochondrial biogenesis. 
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CHAPTER ONE 
MORINGA OLEIFERA AS A POTENTIAL ERGOGENIC AID IN SKELETAL MUSCLE 
Introduction 
The benefits of physical activity are numerous, including increased skeletal muscle 
metabolism and preventing loss of mass, decreasing adipose tissue mass, improved cognition and 
preventing chronic diseases, such as coronary artery disease, stroke, diabetes and cancer [1-3]. 
However, because some individuals may not be able to participate in physical activity for various 
reasons, it is critical that alternative solutions to increase skeletal muscle metabolism and 
decrease adipose tissue mass are developed, such as ergogenic aids.  An ergogenic aid is 
something that improves the performance capacity of exercise or enhances training adaptations 
[4-6].  They may also enhance energy production, provide individuals with a competitive 
advantage, prepare an individual to exercise, improve exercise efficiency, recovery time, or assist 
in injury prevention during intense training [4, 5].  An ergogenic aid may involve a training 
technique, mechanical device, nutritional ingredient, pharmacological method, or physiological 
technique [4, 5]. Due to the competitive nature of sports, performance enhancing substances or 
ergogenic aids have become more popular [7].   
More recently, there has been more focus on the contribution of nutrition and dietary 
supplements to optimize training and athletic performance [17-21].  Research shows that roughly 
50% of the general population [18] and about half of all athlete’s report using supplements [19].  
However, ergogenic aids that are classified as supplements are not required by law to be 
scientifically evaluated, which means the contents of these products and the claims on the label 
have not been evaluated by the U.S. Food and Drug Administration, and thus, may not have any 
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scientific basis [18].  A nutritional supplement is only defined as an ergogenic aid if peer-
reviewed studies demonstrate that the supplement can significantly enhance metabolism or 
exercise performance after weeks to months of ingestion [17].    
One common category of nutritional supplements are herbals and botanicals, which have 
become the most popular ergogenic aids on the market, in part due to the perception over the past 
few years that natural means healthy [22, 33, 34].  Plants contain nutrients and phytochemicals, 
thus providing essential and secondary metabolites, which are at the forefront of research due to 
their potential biological properties [35].  Approximately 7% of the U.S. population uses herbal 
supplements to enhance muscle growth, burn fat, improve endurance, or increase strength 
performance [34, 35].  Clinical outcomes have varied in previous studies due to factors such as 
the type of plant, soil type, geographic location and the method of extraction used [34].  
Moreover, most studies only highlight the efficacy of the herb and do not mention probable risks 
or negative side effects to athletes [34].  Although research findings support the beneficial 
medicinal effects of specific herbs for specific health problems, research investigating the 
ergogenic effects of herbal supplements is limited [35].   
Therefore, in the present study, we aim to investigate the role of Moringa oleifera (M. 
oleifera) in mouse skeletal muscle, a popular tropical and sub-tropical plant used to treat 
hundreds of common diseases and ailments, and importantly, is also believed to be a potential 
ergogenic aid.  Specifically, there is significant evidence in literature that M. oleifera modulates 
metabolism and exerts anti-inflammation and -oxidant properties; however, there is not enough 
evidence on the underling mechanism of action of M. oleifera on skeletal muscle and its 
ergogenic aid effects.  The present study is also designed to evaluate if M. oleifera attenuates 
oxidative stress, improves metabolism, and promotes endurance capacity by increasing 
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mitochondrial biogenesis and fiber-type switching in mouse skeletal muscle.  We hypothesize 
that M. oleifera will increase endurance capacity in adult mouse skeletal muscle via key 
metabolic signaling pathways.  We will rigorously test this hypothesis using three specific aims: 
1) Aim 1: We will evaluate endurance capacity and fiber-type switching following M. oleifera 
supplementation and delineate the specific underlying mitochondrial signaling pathways;  2) 
Aim 2: We will examine the effects of M. oleifera on glucose metabolism in adult skeletal 
muscle and 3) Aim 3: We will investigate the effects of M. oleifera on angiogenesis and 
microcirculation in adult skeletal muscle.  Collectively, these specific aims will examine 
whether M. oleifera is an effective ergogenic aid and evaluate its use in the regulation of 
metabolism and circulation in skeletal muscle. 
  
Skeletal Muscle & Performance 
Skeletal muscle is the most abundant tissue in the body of healthy individuals and is 
essential for motion and support [2].  In the adult human body, it comprises about 40-50% of the 
total body mass, with more than 600 individual muscles [1].  For this reason, skeletal muscle is 
the key determinant of basal metabolic rate (BMR), energy metabolism [2] and  the major 
consumer of glucose, and is responsible for about 80% of insulin-mediated glucose uptake and 
fatty acid metabolism [2].  Furthermore, it can increase energy expenditure up to 30-fold during 
intense exercise by stimulating insulin-independent glucose uptake and increasing higher fatty 
acid uptake and oxidation [2].  Muscle tissue also plays a vital role and expends a significant 
amount of energy in maintaining muscle mass through protein synthesis, repair, and regeneration 
[2].   
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The loss of muscle mass can lead to physical and metabolic dysfunction [3].  
Furthermore, a sedentary lifestyle or inactivity can lead to an increased risk of chronic diseases, 
such as coronary artery disease, stroke, diabetes, and cancer [8].  There is sufficient research 
demonstrating that physical activity provides the cardiovascular, neuroendocrine, respiratory, 
and musculoskeletal systems positive benefits [8].    Physical activity can reduce adipose tissue 
mass (obesity), improve glucose metabolism, and decrease the risk of metabolic syndrome [8].  
Aerobic training (endurance) is associated with improvements in metabolic regulation, but 
current research suggests it may also promote skeletal muscle hypertrophy [9].  Skeletal muscle 
plays an important role in glucose homeostasis because it has the ability to take up glucose and 
store it, which aids in controlling blood glucose levels [10].  Glucose metabolism and skeletal 
muscle hypertrophy (protein synthesis) are crucial to maintaining a healthy weight and living a 
better quality of life.  Physical activity is known to promote molecular changes in skeletal muscle 
including fiber-type switch, increasing mitochondrial biogenesis, angiogenesis, and oxidative 
capacity [11, 12].         
 
Molecular Pathways Associated with Mitochondrial Biogenesis 
 Skeletal muscle fibers contain mitochondria which play a role in muscle contraction and 
energy production by generating ATP [13] through a process known as oxidative 
phosphorylation [13].  Mitochondrial biogenesis involves the growth or proliferation of pre-
existing mitochondria, a process dependent on the coordination of nuclear and mitochondrial-
encoded gene expression [13].  In response to stimuli, like endurance exercise, mitochondrial 
content increases because of the increase in capacity for sustained work [14].  Mitochondrial 
biogenesis is a complex process because mitochondria are comprised of proteins derived from 
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the nuclear and mitochondrial genomes [14].  For four decades, scientists have known that when 
muscle is exercised over long periods of time, mitochondrial content increases, which improves 
the tissue’s capacity for oxygen consumption and ATP provision [14].  Mitochondrial biogenesis 
has many applied health benefits including improved muscular endurance and reduced 
fatiguability during normal daily activities [14].   
The major steps involved in mitochondrial biogenesis include stimuli-induced activation 
of kinase/phosphatase signaling, such as what occurs with endurance exercise [14].  The 
kinase/phosphatase activation then activates transcription factors, mRNA stability proteins, 
and/or translation factors [14].  This leads to the translation of precursor proteins, followed by 
the import of proteins into mitochondrial compartments, leading to two different pathways [14].  
First, the import of proteins can cause the assembly of multi-subunit complexes, which results in 
the increase in muscle aerobic capacity [14].  Second, the import of proteins can lead to mtDNA 
transcription and copy number, causing mtDNA-encoded proteins to assemble multi-subunit 
complexes, which results in the increase in muscle aerobic capacity [14].     
In 1967, the first direct evidence of exercise training-induced mitochondrial biogenesis in 
skeletal muscle following treadmill running exercise was reported [13, 15].  More recently, 
studies have shown that mitochondrial dysfunction in skeletal muscle has been associated with 
the development of metabolic diseases [11].  Mitochondrial dysfunction can lead to a decrease in 
exercise performance and tolerance [2, 11, 16]. However, exercise can be the best treatment of 
many of these metabolic diseases [11].  Therefore, understanding the mechanisms of 
mitochondrial function in skeletal muscle in response to disease, training, injury, diet or other 
conditions is critically important.   
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The molecular mechanisms associated with skeletal muscle changes in response to 
aerobic exercise are well established [12].  Exercise can regulate a vast array of biological 
functions in the body [17], including cellular processes within skeletal muscle like fatty acid 
metabolism, and glucose and protein metabolism via the induction of a range of signal 
transduction pathways [17].  Most studies of exercise signaling have focused on the transient 
changes in phosphorylation of kinases, specifically AMP-activated protein kinase (AMPK), 
Ca2+/calmodulin-dependent protein kinases (CaMKs), and mitogen-activated protein kinases p38 
MAPK and ERK1/2 [12] [17].  Research has also established that acute exercise can activate 
signaling pathways, which alters the activity of coactivators and transcription factors, along with 
expression of genes that play a role in the regulation of angiogenesis, mitochondrial biogenesis, 
carbohydrate and lipid metabolism, and proteolysis [12].  Exercise causes acute metabolic and 
mechanical demands in the activated muscles, which requires the regulation of diverse signaling 
pathways that form a complex signaling network [17].  This network produces cellular 
homeostatic adaptations [17].  For example AMPK, plays an important role in whole body 
metabolic homeostasis and is a target for the effects of the antidiabetic drug, metformin [17].  
However, research has yet to discover the full effects of AMPK’s biological targets and narrow 
down the specific phosphorylation sites [17].   
 Other key molecules include peroxisome proliferator-activated receptor gamma 
coactivator-1 (PGC-1), a family member of transcriptional coactivators (PGC-1α, PGC-1β, and 
PRC), which have been identified as key regulators of mitochondrial function [11, 12].  In 
response to exercise, PGC-1α was the first transcriptional coactivator identified by its ability to 
interact with peroxisome proliferator-activated receptor gamma (PPARγ) transcription factor 
[11] [18].  More importantly, PGC-1α is an important regulator of exercise-induced adaptations 
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in skeletal muscle and has been shown to be induced in skeletal muscle in response to exercise 
[11] [19, 20].  Mitochondrial transcription factor A (TFAM) and PGC-1α are thought to be 
master regulators of mitochondrial biogenesis and adaptation of skeletal muscle in response to 
aerobic exercise [12, 13].  PGC-1α functions in the nucleus by controlling the expression of 
nuclear respiratory factors 1 and 2 (Nrf-1 and Nrf-2), which are responsible for controlling the 
expression of TFAM [13].  
 PGC-1α has a primary role in promoting mitochondrial biogenesis (Figure 1) [13].  An 
increase in PGC-1α expression can lead to expression of mitochondrial enzymes in the electron 
transport chain (ATP synthetase, cytochrome c oxidase subunits) [13].  One study has shown that 
overexpression of PGC-1α leads to upregulation of 151 genes [13], which are known to encode 
mitochondrial proteins involved in various metabolic functions [13].  Furthermore, endurance 
exercise induces mitochondrial biogenesis by promoting PGC-1α expression through 
transcriptional control and activity through post-translational modification [13].  Expression of 
PGC-1α mRNA, specifically over-expression or induction in skeletal muscle, have mimicked 
many effects of exercise on mitochondrial biogenesis [13].  In PGC-1α knockout mice, normal 
exercise training induced fiber-type transformation, but mitochondrial biogenesis and 
angiogenesis was significantly attenuated in the skeletal muscle [13].  These data suggest that 
PGC-1α is necessary for exercise-induced mitochondrial biogenesis in skeletal muscle.  
 Mitochondrial biogenesis in skeletal muscle can be promoted and controlled through the 
activation of PGC-1α and consequent translocation to the nucleus [13].  It has been shown that 
silent mating-type information regulation 2 homolog 1 (SIRT1) deacetylates PGC-1α, and SIRT1 
activation is associated with increases in PGC-1α target gene expression [13].  It is suggested 
that SIRT1 activates PGC-1α through deacetylation, but this activity depends on prior 
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phosphorylation of PGC-1α  by AMPK, which integrates both contractile and metabolic cues in 
exercise-induced skeletal muscle adaptation [13].    
 
Mitochondrial Dynamics and Maintenance 
 In skeletal muscle, mitochondria form a network with the subsarcolemmal and 
intermyofibrillar population [13].  The intermyofibrillar mitochondria provide immediate high 
energy for contractile activities due to their proximity to the contractile apparatus [13].  Fusion is 
the joining of nearby individual mitochondria and fission is the separation of nearby 
mitochondria [13, 21].  These two processes are important in controlling mitochondrial structure 
and function [13, 21].  In healthy, metabolically active cells, there can be a large interconnected 
network of mitochondria, and dysfunctional mitochondria are separated from the network and 
removed through a process known as autophagy [13, 21].  
 Mitofusions 1 and 2 (MFN1 and MFN2) are proteins involved in the control of fusion of 
the mitochondrial outer membrane [13, 21].  A protein involved in the control of fusion of the 
mitochondrial inner membrane is MGM1/OPA1 [13].  Fission of the mitochondrial outer 
membrane occurs when a GTPase, dynamin-related protein 1 (DRP1), works with Fission1 
(FIS1) or mitochondrial fission factor (MFF) [13, 21].  Fission and fusion of mitochondrial cells 
is crucial in maintaining healthy mitochondrial populations and cell function [13, 21].  Research 
suggests that exercise regulates both mitochondrial fusion and fission [13, 21], however it has 
been reported that excessive mitochondrial fission was linked to mitochondrial degradation [21].  
It remains unclear how exercise precisely regulates mitochondrial fission and fusion and what 
the relationship of the pre-existing quality of the mitochondrial network region is to the response 
to exercise regimen [13]. 
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 Mitophagy is a category of autophagy and it is a highly selective process that can 
promote the elimination of dysfunctional or unnecessary mitochondria [21].  Damage to the 
mitochondrial network can be caused by toxins, free radicals, or other chemical agents [13].  
Damaged mitochondria cannot fuse with healthy mitochondria and need to be removed for 
skeletal muscle to properly function, specifically contractile and metabolic functions [13].  
Mitophagy is dependent on specific signals present on the damaged or dysfunctional region of 
the mitochondrial network (figure 2) [13, 21].  The most studied pathway of mitophagy involves 
PTEN-induced putative kinase protein 1 (PINK1) and PARKIN (component of a multiprotein E3 
ubiquitin ligase complex) [13, 21].  These proteins relay the signals associated with damage to 
the induction of mitophagy [13]. As the mitochondrial inner membrane becomes depolarized, 
PINK1 stabilizes and recruits PARKIN from the cytosol onto the mitochondrial outer membrane 
[13, 21].  This process leads to polyubiquitination of the mitochondrial outer membrane proteins 
and mitophagy [13, 21].             
 
Molecular Pathways Associated with Endurance Capacity  
Skeletal muscle fibers are multinucleated cells and contain sarcomeres, which are the 
structural contractile unit [13, 22].  The phenotype and gene expression of skeletal muscle fibers 
are categorized based on their specific contractile functions of speed (fast or slow), which is, in 
turn, determined by their contractile protein isoform, and the density of mitochondria (high or 
low) [13, 22].  Human skeletal muscle is comprised of two general types of fibers, type I (slow-
twitch) fibers and type II (fast-twitch) fibers [13, 22].   
Type I fibers are sometimes termed slow oxidative fibers and have the slowest contractile 
speed and a high density of mitochondria, which supports endurance capacity [13].  They contain 
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the myosin heavy chain protein isoform that has a slow contractile speed and uses less ATP per 
unit of work because of its lower myosin ATPase activity [13].  This allows the fibers to be more 
metabolically efficient, while the high mitochondrial density allows an oxidative supply of ATP 
for contractile work [13].  Furthermore, muscle fiber adaptations to endurance exercise may be 
restricted to intrinsic ranges within a given fiber type that limit mechanical adaptations [13].   
Type II fibers have poor aerobic endurance capacity compared to type I fibers [13].    In 
humans, faster contracting muscle fibers have two common classifications, fast oxidative (type 
IIa) and fast oxidative-glycolytic (type IIx) [13, 22].  Rodents contain a third type of fast 
contracting fibers, which is classified as fast glycolytic (type IIb) [13].  Each of the three types of 
type II fibers has its own myosin heavy chain (MHC) gene [13, 22].  Furthermore, mitochondrial 
density is high in type I and IIa and is decreased in type IIx and IIb fibers (type IIb fibers contain 
the least number of mitochondria) [13, 22].  A comparison of skeletal muscle fiber types is 
outlined in Table 1. After long periods of inactivity or injury, type I (slow) fibers can switch to 
type II (fast) fibers.  Fiber-type switching refers to the MHC protein and gene isoforms within a 
single fiber “switching” or changing due to physical activity, physical inactivity, electrical 
stimulations, or gene modifications [13].  Increased endurance activity can induce a fiber-type 
switching to a more oxidative fast phenotype, for example in humans, type IIx may switch to 
type IIa with endurance training [13, 22].  Moreover, research suggests that endurance exercise 
increases fiber oxidative capacity without changing the MHC composition, further suggesting 
that the metabolic and contractile differences may be controlled by distinct signaling pathways 
[13].  Endurance exercise also promotes other phenotypic changes including improved insulin 
sensitivity and metabolic flexibility [22-25].  
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Several studies have demonstrated that endurance exercise promotes a fiber type switch 
from a glycolytic to an oxidative phenotype within the fast-twitch fiber types (e.g., MHC type IIx 
to IIa) [22-24, 26, 27].  Both MHC1 and IIa isoforms coexist in human skeletal muscle fibers 
following endurance training, and professional athletes have increased type I fibers, but exercise-
induced fiber type switching to type I fibers remains elusive [22-24].  Advancements in 
molecular genetics have led to research in exercise-induced fiber type transformation [22, 23, 
27].  Some studies have shown that muscle contractions can activate the calcium-calmodulin 
dependent serine/threonine protein phosphatase, calcineurin [22, 28].  Activation of calcineurin 
is thought to promote the expression of slow-twitch muscle genes through dephosphorylation and 
activation of the nuclear factor of activated T-cells (NFAT) [22, 28].  Furthermore, inhibition of 
the calcineurin-NFAT pathway using cyclosporine A (CsA), FK506, calcineurin inhibitory 
protein (CAIN/CABIN-1), or peptide VIVIT lead to a reduction in the percentage of slow-twitch 
fibers and/or blocked slow-twitch muscle promoter activity and gene expression in rodents [22, 
28-30].  Transgenic mice overexpressing a constitutively active form of calcineurin in skeletal 
muscle had an increased number of slow-twitch fibers, as well as elevated expression of slow-
twitch troponin I, myoglobin, glucose transporter 4 (GLUT4), pyruvate dehydrogenase kinase 4 
(PDK4), mitochondrial enzymes, and PGC-1α [22, 31, 32].  Moreover, carbohydrate oxidation 
was decreased, and lipid oxidation increased in skeletal muscle of these mice [22, 32, 33]. 
In adult skeletal muscle, CaMK has also been shown to have a role in exercise-induced 
genetic reprogramming of fiber types [22, 34-36].  The interaction between calcineurin and 
CaMKIV has been shown to stimulate the activities of transcriptional factors, myocyte enhancer 
factor 2 (MEF2) and NFAT [22, 34-36].  It is thought that CaMK activates MEF2 proteins via 
class II histone deacetylases, such as HDAC4, HDAC5, and HDAC9 [22].  These histones 
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interact and inhibit MEF2, which results in the repression of target genes [22, 37].  Deletion of 
HDAC5 and HDAC9 genes demonstrated an increase in type I and IIa fibers in soleus and 
plantaris muscles, whereas muscle-specific inducible expression of an HDAC that cannot be 
phosphorylated prevented running-induced fiber type switching [22, 34-37].  Data from research 
studies suggest that CaMK activates MEF2 through depression of HDACs in fiber type 
transformation [22, 37, 38]. 
As described previously, PGC-1α plays a vital role in endurance exercise-induced muscle 
adaptation [22, 39, 40].  Some studies suggest that overexpressing PGC-1α results in an 
increased percentage of slow-twitch fibers, and improved exercise capacity in mice [22, 39, 40].  
Total knockout, or muscle-specific knockout of the PGC-1α gene (Ppargc1a), results in a 
reduction of the oxidative phenotype in skeletal muscle [22, 41-43].  Deletion of targets upstream 
of PGC-1α, like p38 MAPK, led to normal fiber type transformation (type IIx to IIa), but 
attenuated mitochondrial biogenesis and angiogenesis [22, 44, 45].  More recent research 
revealed that PGC-1α may influence the maintenance of slow-twitch, type I fibers, but it is not 
required for exercise-induce fiber type switching [22].     
 
Vascular Improvements in Skeletal Muscle 
 The metabolic demands of skeletal muscle increase during aerobic endurance exercise 
[13].  Exercise training is associated with a decreased risk of cardiovascular diseases [46]. In 
response to regular physical exercise, the structure and function of the skeletal muscle fibers 
adapt (mitochondrial biogenesis, fiber-type switching), and cardiovascular changes lead to 
additional positive effects [47].  Some of the cardiovascular adaptations to endurance exercise 
include functional changes to the heart and blood vessels [47], more specifically the radius of 
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large vessels increases and there is an increase of muscle capillarity through angiogenesis [22].  
An increase in blood flow to the skeletal muscle during exercise is required to provide an 
additional supply of oxygen and nutrients [22].  More recently, research suggests that the 
smallest diameter vessels, capillaries, may also undergo microvascular remodeling in response to 
continuous training stimulus [47].  Angiogenesis is an adaptive process that causes an expansion 
of the capillary network from pre-existing capillaries [22].  This process improves gas and 
nutrient exchange in peripheral tissues, which is thought to contribute to improved physical 
performance [22].  Angiogenesis promoted by exercise is thought to be mediated by a 
combination of growth factors, hypoxia, and shear and mechanical stresses [22].   
 Angiogenesis in skeletal muscle is a tightly regulated process at many different levels 
[46].  When microcirculation cannot meet the metabolic demands imposed on the muscle by 
cellular and physical influences, these influences exert an upstream effect on the capillary 
network to proliferate, which affects the up-stream input [46].  Muscle fibers and endothelial 
cells can sense the stress from cellular or metabolic demands, which leads to the activation of 
appropriate gene expression [46].  The process of angiogenesis ceases once metabolic 
homeostasis is reestablished [46].  However, this process is multifactorial, and the molecular 
mechanisms are only beginning to be elucidated [46]. 
 The molecular AMPK/PGC-1α/Vascular endothelial growth factor (VEGF) axis is 
thought to play a pivotal role in angiogenesis in skeletal muscle [47].  Research has demonstrated 
that after exercise, endothelial cells and/or the muscle fibers respond to AMPK, sirtuins, and 
PPARs [47].  Data suggests that the presence of VEGF within the muscle fiber is necessary for 
endurance training responses in angiogenesis and oxidative capacity [13].  Furthermore, an 
increase in VEGF expression has been shown to improve running speed and endurance [13].  
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Providing adequate oxygen to the working muscles and mitochondria depends on the 
surrounding capillaries [48].  Low levels of VEGF in skeletal muscle have been associated with 
diminished capillary density [48].  It has also been suggested that VEGF plays a role in the 
regulation of vasodilation in several vascular beds through a nitric-oxide dependent mechanism 
[48].  Studies have demonstrated an increase in VEGF expression in response to exercise [48].  
However, little attention has been given to the requirement of VEGF signaling for maintaining 
the microvascular network in skeletal muscle [48].    
 A single bout of exercise has been shown to induce mRNA expression of multiple 
angiogenic growth factors and related receptors in skeletal muscle, including VEGF (Vegfa) [22].  
Muscle fiber expression and secretion of VEGF has been shown to promote angiogenesis 
through its paracrine effects [22].  However, the signaling cascade within muscle fibers that 
decodes muscle contractile activity signals in regulating VEGF activity has yet to be elucidated 
[22].  It is thought that PGC-1α coactivates the orphan nuclear receptor estrogen-related 
receptor-α (ERRα) [22].  This hypothesis was tested using a whole body knock out of the PGC-
1α gene, which resulted in a reduced VEGF protein expression and blunted response to acute and 
chronic exercise training [22].  The functional role of PGC-1α in exercise-induced VEGF 
expression and angiogenesis may be dependent on p38 MAPK signaling upstream and ERRα 
downstream [22].    
 
Nutritional Interventions & Performance 
Ergogenic Aids 
An ergogenic aid can be a training technique, mechanical device, nutritional ingredient, 
pharmacological method, or physiological technique that can improve exercise performance 
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capacity or enhance training adaptations [4-6].  Ergogenic aids may enhance energy production, 
provide individuals with a competitive advantage, prepare an individual to exercise, improve 
exercise efficiency, improve recovery time, or assist in injury prevention during intense training 
[4, 5].  Due to the intense competitive nature of sports, the use of performance-enhancing 
substances (PESs) has become increasingly popular [7].  Sporting federations have created 
regulations and developed testing programs to detect substances and discourage doping in 
athletics [49].  The World Anti-Doping Agency (WADA) was created in 1999 to address doping 
across sporting disciplines and regions [7, 49].  Detection of banned substances was originally 
done by assaying biological fluids for illicit substances or their metabolites [7, 49].  However, 
these methods were limited to detecting only the substances or their metabolites, but were not 
able to detect synthetic versions of naturally occurring endogenous hormones, like growth 
hormone [49].   
Currently, indirect detection methods are used, which test for the biological effects of the 
substance rather than the substance itself [7, 49].  There are limitations and advantages to both 
detection methods, which means new approaches to anti-doping are needed [49].  A more recent 
method to detection is using performance as a marker for doping [49].  Most people who dope 
with substances or methods, do so with the intention to enhance performance [7, 49].  Therefore, 
raw performance data, profiles, or derived metrics could serve as indirect markers of doping 
[49].  However, using performance markers for doping detection is most reliable in sports like 
track and field, weight lifting, and swimming because the sport settings are relatively 
standardized, the outcome is a discrete, objective measurement of distance covered, mass lifted, 
or time achieved [49].  It may be more difficult to use performance markers as a detection of 
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doping in other sports, like soccer or basketball, due to less standardized competition settings and 
the physical capacity of the athlete may not be the primary determinant of performance [49].    
In 2004, WADA released the first comprehensive list of prohibited substances [7, 49].  
The list breaks down violations into substances and methods.  Substances are classified as 
anabolic agents; peptide hormones, growth factors, and related substances; β2 adrenergic receptor 
agonists; hormone and metabolic modulators; and diuretics and masking agents [7, 49].  
Substances that have not been approved for human therapeutic use are prohibited, even if they 
are not listed [7, 49].  The list of banned methods includes manipulation of blood and blood 
components; chemical and physical manipulation, and gene doping [7, 49].  If a substance or 
method is not listed, it may be considered prohibited if it meets two of the following criteria:  (a) 
it has the potential to enhance sport performance, (b) it represents a health risk to the athletes, or 
(c) it violates the spirit of sport [7, 49].  When an individual decides to use an ergogenic aid, 
whether it be a dietary supplement, method, or other substance, they need to consider the issue of 
efficacy, safety, and legality associated with the product before use [6]. 
  More recently, there has been more focus on the contribution of nutrition and dietary 
supplements to optimize training and athletic performance [4-7, 49].  Dietary supplements are 
used by a variety of individuals, but individuals who participate in athletics and physical activity 
represent the largest portion of the population purchasing these products [6].  Most data reports 
that about 50% of the general population reported using supplements, while about 75% of 
college athletes, 100% of body builders [4], and about half of all athletes reported using 
supplements [6].  There is a wide variation between different sports and between athletes of 
differing performance levels, ages, and cultural backgrounds who have reported supplement use 
[6].  In 2013, the Nutrition Business Journal report estimated that the global supplements market 
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stood at $104 billion, while the sports supplements broke the $10 billion retail value sales mark 
in 2014 [6].    
New ergogenic aids appear on the market almost daily and most are classified as a dietary 
supplement [4].  Aids that are classified as supplements means the contents of the product and 
the claims on the label have not been evaluated by the U.S. Food and Drug Administration 
(FDA), and thus, may not have any scientific basis [4].  Dietary supplements can be defined and 
categorized based on their function, action, or ingredients [50].  Some categories include sports 
foods (gels, bars, drinks, protein powders), vitamins and minerals, herbals and botanicals, or an 
ergogenic supplement [50].  Furthermore, there are specific categories for weight loss, improving 
libido, gluten-free, lactose-free, allergen-free, and functional foods [50].  Functional foods, herbs 
and botanicals, and super food categories are difficult to study and define due to the multiple, 
complex compounds and the heterogenous content of biologically-active ingredients [50].  The 
FDA has defined dietary supplements as, “a product intended for ingestion that contains a 
‘dietary ingredient’ intended to add further nutritional value to (supplement) the diet” [50].  A 
“dietary ingredient” can be a vitamin, mineral, herb or other botanical, amino acid, metabolite, 
constituents, or extracts [50].  
 
Nutritional Supplements as Ergogenic Aids 
It is suggested that a nutritional supplement can be defined as an ergogenic aid if peer-
reviewed studies demonstrate the supplement to significantly enhance exercise performance after 
hours to months of ingestion [5].   This may include, but is not limited to an increase in maximal 
strength, running speed, and/or work during a given exercise task [5].  A supplement may also be 
classified as ergogenic if it can acutely enhance the ability of an athlete to perform an exercise 
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task or enhances recovery from a single bout of exercise [5]. The International Society of Sports 
Nutrition (ISSN) has defined the ergogenic value of supplements more broadly [5].  The view of 
the ISSN is that a supplement is ergogenic if most human studies support the ingredient as being 
effective in promoting further increases in muscle hypertrophy or performance with exercise 
training, but a supplement cannot be classified as ergogenic if data is only supported by cell 
culture or rodent studies [5]. 
Complementary and alternative medicine is defined as the use of medical products and 
practices that are not part of the standard medical care [51].  Plants are widely used around the 
world in the management and treatment of a wide range of ailments and thus, are considered 
complementary and alternative medicine [51-58].  The World Health Organization (WHO) 
estimates that up to 80% of people rely primarily on traditional remedies, such as herbs, for 
medicinal purposes [59].  The medicinal value of certain plants is due to the presence of 
phytochemicals, polyphenols, and their elemental composition [54, 59].   
Polyphenol compounds in plants have been associated with disease prevention or control 
due to the antioxidant properties of their constituents [59].  Plants are also rich in other 
phytochemicals, which are sources of nutrition and medicine for humans [60].  Furthermore, 
herbal and botanical remedies have attracted interest in the research community because of their 
rich source of potential chemical entities for the development of new effective drugs for 
neglected diseases [61].  A group of phytochemicals in plants are antioxidants and include 
chemical compounds such as polyphenols, vitamins, and fatty acids [60].  These chemical 
compounds have been shown to react with unstable oxidants, such as free radical species, like 
reactive oxygen (ROS) and nitrogen species and stabilize them [60].  In humans, an increase in 
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oxidants can lead to oxidative stress causing degenerative diseases like cancer, neurological 
disorders, Alzheimer’s, cardiovascular disease, and pulmonary diseases [60].     
Dietary supplements have become one of the most popular ergogenic aids on the market.  
One category of dietary supplements are herbals and botanicals.  The use of herbal supplements 
has increased over the past few years due in part to the perception that natural means healthy [50, 
62].  Plants provide us with essential nutrients and contain naturally occurring substances, known 
as phytochemicals [63].  Herbal supplements may be derived or extracted from seeds, gums, 
roots, leaves, bark, berries, or flowers of the plant [62, 63].  These supplements contain 
phytochemicals like carotenoids and polyphenols, including phenolic acids, flavonoids, saponins, 
alkaloids, glycosides, and lignans, which are thought to have nutritive or medicinal value [62, 
63].  For example, capsaicin, found in cayenne, red, and chili peppers, have medicinal properties 
that are comparable to caffeine [63].  Caffeine and capsaicin are stimulants, which may induce 
sympathetic activation of the central nervous system, increasing catecholamine secretion and 
enhancing lipid oxidation, thus decreasing the use of glycogen [63].   
Throughout history, herbals and botanicals have been used as medicine, with the earliest 
evidence of human use for healing dating back to the Neanderthal era [63].  Currently, some 
modern medicines may be classified as herbals [63].  In Germany, herbals are regulated as 
medicine, but in the United States, most herbals are regulated by the Dietary Supplement Health 
and Education Act (DSHEA), more like food than drugs [63].  Due to the pharmacological 
effects of herbals, health professionals are emphasizing the need for regulations in order to 
standardize herbal therapy [62, 63]. 
A number of herbal and botanical supplements have not been proven safe and effective 
under current FDA standards and others have been excluded from FDA requirements because 
20 
 
they present a source of drug production [62].  Research has shown that plants provide essential 
metabolites (carbohydrates, lipids, nucleic acids) and secondary metabolites (terpenoids, 
alkaloids, phenolic compounds) [62].  Secondary metabolites have been at the forefront of 
research due to their potential biological properties like anti-allergic, anti-atherogenic, anti-
inflammatory, hepato-protective, antimicrobial, antiviral, antibacterial, anticarcinogenic, 
antithrombotic, cardioprotective, and vasodilatory effects [62].  The biological properties of 
herbs are mediated by a variety of characterisitcs and compounds, such as antioxidant and redox 
properties [62].  The antioxidant characteristics and redox properties play an important role in 
oxidative damage stabilization by free radical neutralization, oxygen scavenging, or 
decomposition of peroxides [62].  This information has led to studies focusing on the role of 
herbal supplements in reducing exercise-induced oxidative stress in athletes [62].  The reduction 
of oxidative stress may enhance muscle recovery and energy maintenance during intensive 
exercises [62].   
As stated earlier, approximately 7% of the U.S. population takes herbal or botanical 
supplements [62, 63] and about 17% of female collegiate athletes reported using herbal or 
botanical supplements [63].  Most herbal supplements used in sports or exercise are used to 
enhance muscle growth and burn fat [62] and are also used by athletes and non-athletes to 
improve endurance and strength performance [62, 63].  However, clinical outcomes have varied 
in previous studies due to factors like the type of the plant, the geographic location from which 
the plant was gathered, and the method of extraction used [62].  Moreover, most studies highlight 
the efficacy of the herb and do not mention probable risks or negative side effects in athletes 
[62].  Research supports the beneficial medicinal effects of specific herbs for specific health 
problems, but research investigating the ergogenic effects of herbal supplements remains limited 
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[63].  The most common perception of herbal supplements is that they are healthy, but some 
natural substances pose a serious health threat, even though they are marketed to improve health 
and physical performance [50, 62, 64].  For example, some natural substances may interact with 
cardiac medications, increase the risk of bleeding when taken with blood-thinning drugs, and can 
cause an overdose if not taken correctly [50]. 
 Athletes need to be aware that some plants may contain doping substances, as well as 
some products based on herbal extracts may be contaminated by agents prohibited by sports [62, 
63].  For example, ma huang, an herbal ephedrine, is a stimulant that may be found in plants and 
is banned by the International Olympic Committee (IOC) [4].   Individuals, specifically athletes, 
who are interested in the performance enhancing benefits of herbal supplements are urged to try 
the supplement in training or simulated competition before implementation in competition [64].  
The effects of most herbal or botanical supplements in sports and exercise remains inconclusive 
[62-64] and more studies investigating the mechanism of action and/or off target effects need to 
be done.   
 
Herbal Medicine as Ergogenic Aids 
 The use of plants and herbal supplements has increased significantly over the past decade 
[62].  Research has demonstrated that herbs have specific beneficial medicinal effects, but 
research investigating the ergogenic effects of herbal supplements is limited [63].  Herbal 
supplements like capsaicin, ginseng, ginkgo biloba, caffeine, and guarana have been used to 
study their ergogenic effects. 
 Ginseng is one of the more popular herbal supplement and is one of the most studied herb 
with regards to physical performance [62, 63].  This plant has been shown to have anti-
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inflammatory and antioxidant properties, as well as stimulate brain function, anabolic and 
immuno-stimulant, and improve endurance performance [62, 63].  Other potential ergogenic 
effects of ginseng include favorable metabolic, hematologic, and cardiovascular improvements 
[63].  Capsaicin, guarana, and caffeine are similar, in that they are stimulants of the central 
nervous system, which increases catecholamine secretions and enhances lipid oxidation [63].  
Ginkgo biloba is thought to exert its mode of action when its active ingredients, the flavonoids 
and terpenoids, work together [62, 63].  Ginkgo stimulates the release of endothelium-derived 
relaxing factor, nitric oxide, which is thought to enhance muscle tissue blood flow through 
improved microcirculation, ultimately improving aerobic endurance by enhancing muscle tissue 
oxidation [63]. 
 There are a variety of herbal supplements that are marketed as ergogenic aids, but there is 
a shortage of well-controlled research evaluating the efficacy of herbal supplements on exercise 
and performance [63].  Most of the knowledge surrounding the efficacy of herbal supplements 
being used as an ergogenic aid is subjective, and research suffers from methodological problems 
[63].  These problems include poor research design and use of a variety of substances where the 
purity and content of the plant is suspect [63].  Future research efforts need to focus on 
experimental design, product purity, standardized dosages, subject compliance, and statistical 
power [63].  Due to the attention and popularity of herbal supplements, it is imperative to have 
quality quantitative evidence to provide to the population.          
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Moringa oleifera  
Plant Background 
Moringa oleifera (M. oleifera) is a tropical and subtropical plant species belonging to the 
Moringaceae family (Papaverales Order) (Figure 3) [54, 65-67].  This plant is commonly 
referred to as Moringa, drumstick tree, horseradish and ben oil tree [68, 69].  M. oleifera is 
widely cultivated around the world, especially in sub-Himalayan regions of Northwest India [52, 
53, 58, 59, 67, 70].  However, it can grow under a variety of conditions in tropical and 
subtropical areas throughout Africa, Saudi Arabia, Southeast Asia, the Caribbean Islands, and 
South America, that may be both humid and hot dry lands and can even survive in less fertile 
soils [59-61, 65-67, 71, 72].  It is a fast-growing and is widely cultivated for its young seed pods 
and leaves (Figure 4), which are used as vegetables and traditional herbal medicine.  The seed of 
the plant can also be processed and used for water purification [68, 69, 73].   
M. oleifera can grow to heights of up to 40 feet, with a trunk diameter of 1.5 feet.  The 
bark is a whitish-grey color and is surrounded by thick cork.  The flowers contain yellowish-
white petals and are fragrant and asexual (Figure 4).  Flowering begins within the first four to six 
months after planting.  However, in cooler climates, flowering only occurs once a year between 
April and June, and in more constant higher temperatures, flowering can occur twice or all year 
round.  The fruit of M. oleifera looks like giant bean-pods about 20-45 cm long (Figure 4) and 
contains dark brown, globular seeds with a diameter around 1 cm (Figure 4).  The seeds are 
dispersed by wind and water and the plant is trimmed and cut down annually to about 3-6 ft to 
increase its leaf biomass.  This is done so the pods and leaves remain within arm’s reach [68, 69, 
73-75].  
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There are 13 known varieties of Moringa species that exist, but M. oleifera is the most 
widely known and used [52, 54, 65].   Different parts of M. oleifera may have nutritional, 
prophylactic and therapeutic properties [58].  Most of the plant parts, including the root, bark, 
gum, leaf, fruit (pods), flowers, seed, and seed oil of M. oleifera are consumed and added to the 
daily diet in a number of different cultures [59, 72] or used as herbal therapies for various 
ailments [51, 65, 72].  M. oleifera is an easily accessible and inexpensive plant and may have 
complementary therapeutic affects [72].   For this reason, it is commonly used as a medicinal 
herb to treat common diseases and ailments, such as inflammation-related disorders, diabetes, 
obesity, cancer, HIV, blood pressure and epilepsy [52-58].  However, there is still a need to 
conduct more extensive research to validate its traditional therapeutic effects cited above. 
 
Phytoconstituents of Moringa oleifera 
M. oleifera plant contains a variety of phytochemicals, such as zeatin, quercetin, beta-
sitosterol, kaempferol, and caffeoylquinic acid, terpenoids, alkaloids, tannins, steroidal aglycones 
and reducing sugars, as well as other bioactive compounds like glucosinolates and 
isothiocyanates [54, 66], which exert multiple pharmacological activities cited earlier, including 
anti-inflammatory, anti-bacterial, anti-oxidant, anti-cancer, hepatoprotective, and neuroprotective 
activities [52, 65, 66].  Chlorogenic acid in M. oleifera has been shown to lower blood glucose 
[66].  Phytochemicals or phytoconstituents also provide color, act as anti-feedants, or protect 
macromolecules [76] and when consumed by humans, phytoconstituents exert bioactive 
properties, including antioxidant, anti-inflammatory, and vasoactive [76].  Studies have shown 
improvements in disease outcomes and tissue function, such as in endothelial function, blood 
pressure, and circulating lipoproteins when plants rich in these phytoconstituents are consumed 
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[76].  A hundred grams (100 g) of dry M. oleifera leaf powder contains 9 times the vitamin A of 
carrots, 15 times the potassium of bananas, 17 times the calcium of milk, 12 times the vitamin C 
of oranges, and 25 times the iron of spinach [66]. For this reason, M. oleifera has been used to 
supplement malnourished populations and mitigate a variety of disorders, such as diabetes 
(hyperglycemia), HIV, cancers and other diseases and conditions [52, 61, 66, 67, 71, 77].   
Because of the high number of M. oleifera phytochemicals, only a few will be briefly 
reviewed here. Zeatin is a plant hormone and a member of the cytokinin growth hormone family 
[78].  It has been reported to have anti-aging effects on human skin fibroblasts [78].  Quercetin is 
a polyphenolic flavonoid with potential chemo-preventive activity [78].  It has also been shown 
to produce antiproliferative effects resulting from the modulation of epidermal growth factor 
receptor (EGFR) or estrogen-receptor mediated pathways, but the exact mechanism of action has 
not been elucidated [78].  Furthermore, research has demonstrated that quercetin also produces 
anti-inflammatory and anti-allergy effects mediated through the inhibition of lipoxygenase and 
cyclooxygenase pathways [78].  Beta-sitosterol is a phytosterol, which when oxidized acquire 
anti-carcinogenic and anti-atherogenic properties [78].  However, their exact mechanism of 
action is not fully understood [78].  Kaempferol is a natural flavonoid that has been shown to act 
as an antioxidant by reducing oxidative stress and is being investigated as a possible cancer 
treatment [78].  Research also suggests that it may be an antibacterial agent [78].  Caffeoylquinic 
acid is an alkyl caffeate ester that may have a role in the inhibition of the NFκB pathway, as an 
anti-neoplastic agent, and an antioxidant [78]. 
  The other key bioactive compounds in M. oleifera are glucosinolates and 
isothiocyanates [79].  Glucosinolates are plant secondary metabolites that are known for their 
fungicidal, bactericidal, nematocidal, and allelopathic properties [80], whereas isothiocyanates 
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are derived from glucosinolates [76].  Sulforaphane is an isothiocyanate from broccoli and has 
been shown to induce expression of mammalian cyto-protective proteins through the Keap1-
Nrf2-ARE pathway [79].  Furthermore, sulforaphane has been shown to inhibit enzymes 
responsible for the activation of carcinogens and induces detoxification enzymes [80]    
 
Extraction Methods 
Various types of solvents have been used to extract a set of desired bioactive compounds 
for research and therapy and the most common include aqueous, ethanolic and methanolic [66, 
71].  Furthermore, the extraction method, along with the part of the plant used, will affect the 
phytochemical content.  Table 2 lists the constituents based on the part of the plant and solvent 
used for extraction [66].  The pharmacological activity of M. oleifera is listed in Table 3. 
To extract specific phytoconstituents from the leaves using polar and non-polar methods, 
the leaves must first be dried and hand-milled [54].  The dried leaves are then extracted by 
successive maceration for 48 h with hexane at room temperature followed by filtration [54].  The 
residue is then extracted again, but this time with absolute ethanol followed by filtration [54].  
The final residue is discarded, and the filtrates concentrated under vacuum to eliminate the 
solvent [54].  As a result, this method of extraction yields two different extracts:  a dark green 
greasy hexane extract and a dark green semisolid ethanol extract [54].  A UHPLC analysis of the 
ethanol crude extract is used to identify a characteristic flavonoid and a mass spectroscopy 
negative ion mode is applied to identify the presence of fatty acids in the non-polar extract [54].  
The UHPLC analysis of the ethanol extract contains Kaempferol-3-glucoside [54].  This extract 
is used for pain and inflammation treatment and research [54]. 
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An increasing amount of experimental research and epidemiological evidence suggests 
that M. oleifera has anti-diabetic and antioxidant effects against the harmful damages of 
oxidative stress and diabetic complications [81] [82].  Several studies have also shown that M. 
oleifera has beneficial effects on carbohydrate metabolism via several mechanism, including 
preventing and restoring the integrity and function of pancreatic β-cells; increasing insulin 
action; improving glucose uptake and utilization [81] [82].  During adipogenesis, it has been 
shown that M. oleifera improves adipocyte functionality and upregulates the expression of 
uncoupling protein (UCP1), sirtuin 1(SIRT1), and peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC-1α), which is involved in thermogenesis by modulating lipid 
metabolism [81].  Furthermore, it is thought that mitochondrial proton leak (UCP activity) might 
play a role in the pathophysiology of diabetic complications and cardiovascular diseases [81].  
Collectively, these data suggest that M. oleifera may exerts its effects intracellularly by 
modulating several metabolic pathways within the mitochondria [81].  However, most of the data 
have been limited to the investigation of M. oleifera role in the liver, kidney, or heart tissue using 
methanolic extraction methods.    
 
Moringa oleifera & Exercise Performance 
 While the overall underlying mechanism of action of M. oleifera in most disorders is not 
fully understood, research conducted thus far has demonstrated its overall biological effects and 
its ability to regulate the function and expression of different proteins in the body.  For example, 
it has been shown that M. oleifera improves adipocyte functionality and upregulates the 
expression of SIRT1 and PGC-1α involved in thermogenesis and modulation of lipid metabolism 
[81].  Based on these and other findings, we hypothesize that M. oleifera may improve exercise 
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performance by upregulating expression of PGC-1α in skeletal muscle tissue, which may 
subsequently induce or facilitate mitochondrial biogenesis and endurance capacity.  Furthermore, 
we speculate that supplementation with M. oleifera could increase SIRT1 deacetylase activity in 
skeletal muscle, which would then promote mitochondrial biogenesis. 
  
Specific Aims and Hypotheses 
 With roughly 50% of the general population and athletes reportedly using supplements, 
there is an urgent need to fully understand the effects and associated side effects of these 
substances.  Although there is significant evidence in literature that shows that M. oleifera 
modulates metabolism and exerts anti-inflammation and -oxidant properties, there is not enough 
data on the specific underlying mechanism of action of M. oleifera on skeletal muscle and its 
ergogenic aid effects.  The present study will investigate M. oleifera’s ergogenic effects on 
skeletal muscles, namely whether there is improvement in performance, change in metabolism, 
microcirculation and induction of mitochondrial biogenesis or switch in fiber-type.   
The exact M. oleifera phytochemical that is responsible for inducing its ergogenic effects 
are not known. We do know that M. oleifera leaves contain several phytoconstituents, such as 
quercetin, zeatin, and methionine, as well as biological compounds like isothiocyanates.  The 
leaves also contain an abundance of secondary metabolites, principally polyphenols and four 
unique M. oleifera isothiocyanates (MICs) [57].  MICs have strong biological activity and are 
thought to be the principal therapeutically active constituents found in M. oleifera [57] and 
perhaps maybe the phytochemical responsible for M. oleifera’s ergogenic effects.  We 
hypothesize that M. oleifera will increase endurance capacity in adult skeletal muscle via key 
metabolic signaling pathways.  We will rigorously test this hypothesis using three specific aims:  
29 
 
1. Specific Aim 1: We will evaluate endurance capacity and fiber-type switching 
following M. oleifera supplementation and delineate the specific underlying 
mitochondrial signaling pathways,  
2. Specific Aim 2: We will examine the effects of M. oleifera on glucose metabolism in 
adult skeletal muscle,  
3. Specific Aim 3: We will investigate the histological effects of M. oleifera by 
examining changes in skeletal muscle angiogenesis and microcirculation of adult 
animals.  
Collectively, these specific aims will rigorously examine whether M. oleifera is an effective 
ergogenic aid and evaluate its use in the regulation of metabolism and circulation in 
skeletal muscle. 
 
Materials & Methods 
Overview of Experimental Design  
Adult, sexually mature male C57BL/6 mice will be divided into four treatment groups:  
1) Negative control group (N = 10), 2) M. oleifera supplemented group (N = 10), 3) Negative 
control + volunteer wheel running (VWR) (N = 10),  or 4) M. oleifera + VWR (N = 10).  We will 
use C57BL/6 mice because they are the most widely used inbred strain and they are commonly 
used for general purposes.  Male mice will be used due to the lack of estrous cycle and thus, the 
absence of hormones that could potentially alter results.  Skeletal muscle tissue from the 
gastrocnemius will be dissected into three equal pieces for analysis, including histological and 
quantitative real-time PCR to evaluate the effect of M. oleifera on protein and gene expressions 
associated with skeletal muscle metabolism, including signaling factors implicated in 
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mitochondrial biogenesis, endurance capacity, mitophagy (fission/fusion) and angiogenesis.  
Muscle capillarity will be assessed in histological sections.    
 
Animals & Supplementation of M. oleifera 
Sexually mature male (6-8 wks) C57BL/6 mice will be individually housed in a specific 
pathogen-free animal facility with a 12-12h light-dark cycle.  Each mouse will be fed at 6:30 am 
every day to ensure the light/dark cycle of the room is kept constant.  They will be fed their M. 
oleifera supplemental pellet first to ensure they eat the whole pellet, then 5.000g of mouse chow.  
What remains of the 5.000g will be taken out and subtracted from the feed the next day when the 
mouse receives the next feeding.  All the mice will be able to drink water throughout the day and 
night without restriction, and the total volume drank will be measured.  The ingredients of the M. 
oleifera pellet will be as follows:  1) 2.0 g bleached & enriched cassava flour, peanut butter (a 
pinch for flavor), 3.32 mL DI water, and 0.070 g M. oleifera leaf powder.  All animal 
experiments will be approved by the IACUC of Georgia State University and Appalachian State 
University and will conform to the National Institutes of Health (NIH) guidelines.  Following the 
3-week supplementation of M. oleifera, half of the mice from each group will participate in 
VWR for an additional 2-weeks to examine if M. oleifera increases endurance capacity [83].  
During the VWR testing, all groups will continue respective treatments.  The animals will be 
killed by CO2 asphyxiation, and their gastrocnemius muscles dissected and either snap frozen or 
fixed immediately.  Figure 5 demonstrates the timeline of treatment with M. oleifera or vehicle 
control, VWR, and harvesting of skeletal muscle tissues.   
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Volunteer Wheel Running 
 Following 3-weeks of M. oleifera or vehicle control supplementation, half of the mice 
from each treatment group will have access to a running wheel every night for 2-weeks.  The 
mice will be separated into single cages that have a running wheel.  The distance of each mice 
will be tracked nightly and the average distances of each treatment group will be calculated and 
compared using a student’s t-test.   
 
Quantitative RT-PCR 
 Total RNA will be extracted from the gastrocnemius muscle via homogenization using a 
RNeasy purification kit and treated with DNase, which will then be used for the reverse 
transcription protocol.  Reverse transcription is the process of converting RNA to cDNA using a 
reverse transcriptase enzyme and dNTPs.  Total RNA will be used to prepare cDNA to ensure a 
global cDNA is produced that is representative of all the RNA transcripts in the sample using 
random primers and the Superscript III first strand synthesis kit.  Relative levels of mRNA will 
be determined by real-time quantitative PCR using an Applied Biosystems cycler and the 
TaqMan Universal PCR master mix. Taqman primers for 18s, PPARγ, PGC-1α, MYLRF, and 
VEGFa will be used.  Table 3 lists the gene name, primer name, and forward and reverse gene 
sequences used to design the primers of interest.  After amplification, data will be normalized to 
18S levels and analyzed by delta Ct method.  Triplicates will be included per group, and 
experiments will be repeated at least twice.  
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Immunohistomchemical Staining Procedure for Capillary Density 
An indirect immunoperoxidase staining technique will be used to stain for collagen type 
IV.  This method is based on antibodies directed against collagen type IV followed by 
development with secondary enzyme-labelled antibody and substrate.  Collagen type IV is the 
only collagen present in the basement membrane, is only present in capillaries, and can be used 
to measure the capillary density.  Muscles will be histologically processed to evaluate the degree 
of capillarity.  Briefly, tissues will be harvested and embedded in OCT and immediately frozen 
in isopentane cooled in liquid nitrogen.  The muscles will be cut transversely in serial sections at 
10μm beginning at the mid-belly of the muscle.  After tissues are sectioned using a cryostat, the 
sections will be fixed in acetone for 10 min.  After fixing, the sections will be washed for 1 min 
in TBS buffer and then washed in PBS buffer for 5 min.  The sections will be incubated in 10% 
w/v normal swine serum in PBS for 10 min and then incubated for 30 min with rabbit-anti-
collagen IV antibody diluted in 10% human AB serum in PBS (1:7500) and then washed in PBS 
for 10 min.  After the slides are wiped gently, they will be incubated for 30 min with peroxidase-
labelled swine anti-rabbit IgG diluted in 10% v/v human AB serum in PBS (1:50).  After 
washing for 5 min with PBS and 5 min with distilled water, the slides will be incubated with 
carbazole buffer for 10 min and washed for 10 min with distilled water.  The sections will be 
mounted with Permount. 
The stained slides will be viewed under a Leica light microscope at the magnification of 
90x, photographed, and copied.  An area with at least 100 fibers in each sample will be selected 
and used for the capillary counting.  Transversely cut capillaries in the area will be counted.  If a 
capillary is sectioned longitudinally, it will be counted as one each time it crossed a junction 
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between three or more fibers.  Capillaries per fiber will be calculated as the number of capillaries 
in the area divided by the number of fibers in the area.   
 
Statistics 
 Data will be presented as means ± SE.  All experiments will be performed with 
independent tissue isolates from at least three different animals for each treatment condition.  All 
measures or reactions will be performed in triplicate.  A two-way ANOVA will be used to 
determine significant differences using SPSS.  Significance will be accepted at p < 0.05.    
 
Conclusion      
This study aims to investigate the role of Moringa oleifera as a potential ergogenic aid.  
M. oleifera has shown to be a promising medicinal therapeutic in combating a variety of 
ailments, conditions, and diseases.  Specifically, there is significant evidence that M. oleifera 
modulates metabolism and exerts anti-inflammation and -oxidant properties.  There is currently 
no substantial evidence demonstrating the underlying mechanism of action of M. oleifera on 
skeletal muscle and its ergogenic aid effects.  The current study is designed to evaluate the role 
of M. oleifera on skeletal muscle, specifically evaluating the effects on oxidative stress, 
metabolism, and endurance.  We hypothesize that M. oleifera will increase endurance capacity 
in adult skeletal muscle via key metabolic signaling pathways.  Furthermore, we aim to delineate 
the specific underlying mitochondrial signaling pathways associated with endurance capacity and 
fiber-type switching, as well as investigate the role of M. oleifera on glucose metabolism, 
angiogenesis, and microcirculation in adult skeletal muscle.  These specific aims will examine 
whether M. oleifera is an effective ergogenic aid, evaluate its use in the regulation of 
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metabolism and circulation, and discern signaling pathways in skeletal muscle it may 
affect.   
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CHAPTER 2 
MORINGA OLEIFERA IMPROVES SKELETAL MUSCLE METABOLISM AND 
RUNNING PERFORMANCE IN MICE 
Introduction 
Moringa oleifera (M. oleifera) is a tropical and subtropical plant that contains a variety of 
phytochemicals and bioactive compounds harvested for its medicinal qualities, including anti-
inflammatory, antibacterial, antioxidant, anti-cancer, hepatoprotective, and neuroprotective 
activities [1-3].  For example, M. oleifera has been used to treat inflammation in rats and it 
inhibits the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide (iNOS) in 
macrophage cell culture, key factors that drive the inflammatory response [4-6].  Further, pre-
treatment with M. oleifera leaf extract prevented lipid peroxidation in the liver by effectively 
restoring available pools of glutathione (GSH) [6, 7].  While the mechanism of action of M. 
oleifera in most disorders is not fully understood, most research has demonstrated a significant 
impact on substrate metabolism.  
 Several studies have shown that M. oleifera has beneficial effects on carbohydrate 
metabolism, such as restoring the integrity and functionality of pancreatic β-cells, increasing 
insulin action, and improving glucose uptake and utilization [8, 9].  M. oleifera improves 
adipocyte functionality during adipogenesis and upregulates key signaling factors implicated in 
lipid metabolism, including uncoupling protein-1 (UCP1), sirtuin 1(SIRT1), and peroxisome 
proliferator receptor gamma coactivator 1 alpha (PGC-1α) [8].  Interestingly, PGC-1α is an 
important regulator of exercise-induced adaptations in skeletal muscle [10].  Further, 
mitochondrial transcription factor A (TFAM) and PGC-1α are thought to be master regulators of 
mitochondrial biogenesis in skeletal muscle following aerobic exercise [11, 12].  Within 
45 
 
mitochondria, PGC-1α can also increase content of enzymes associated with the Krebs Cycle, 
fatty acid oxidation, oxidative phosphorylation, and electron transport chain [13].   Collectively, 
these data suggest that M. oleifera may exert its effects intracellularly by modulating several 
metabolic pathways within the mitochondria, or by increasing total mitochondrial density [8].  
While the majority of M. oleifera research quantifies adaptations in liver, kidney, or heart tissues, 
M. oleifera may exert similar effects in skeletal muscle.    
Approximately 7% of the U.S. population takes herbal or botanical supplements to 
improve endurance and strength performance [14, 15].  For example, ginseng, a Chinese herb 
used for the past two centuries, stimulates brain function, enhances protein synthesis, and 
improves endurance performance in humans [14, 15].   Quercetin, a bioflavonoid isolate of M. 
oleifera, increased skeletal muscle PGC-1α expression, attenuated insulin resistance, minimized 
fat mass accumulation, and increased energy expenditure in rodents and humans [16].  Further, 
rats supplemented with M. oleifera had a delayed onset of fatigue and swam for longer periods of 
time during a forced swim test [17], suggesting that M. oleifera could be an effective ergogenic 
aid. 
Increased endurance-like activity is also associated with increases in vascular endothelial 
growth factor (VEGF), which plays a vital role in stimulating angiogenesis and increasing 
capillary density in skeletal muscle [11].  Interestingly, M. oleifera supplementation upregulated 
the angiogenic marker, VEGF, in wounded tissue from diabetic rats [18].   Further, angiogenesis 
was stimulated in fertilized whit leghorn chicken eggs that received M. oleifera supplementation 
[19].  Together, these data suggest that M. oleifera supplementation stimulates vascular 
remodeling and may improve blood flow. However, the role M. oleifera supplementation might 
play in vascular remodeling in skeletal muscle and performance remains unknown.  
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Endurance-like activity may also promote skeletal muscle hypertrophy [20, 21].  
Published research examining the effects of M. oleifera and the maintenance of skeletal muscle 
mass is limited. However, M. oleifera supplementation has been successfully used to improve 
skeletal muscle mass in atrophied muscles in an experimental model of malnutrition [22].  
Furthermore, skeletal muscle atrophy was blunted in obese rats that received quercetin extract 
[23].  Importantly, skeletal muscles from these obese rats reported lower levels of atrogin-1, an 
E3 ligase associated with skeletal muscle atrophy. Taken together, these data suggest that M. 
oleifera may also play a role in altering markers of skeletal muscle protein balance, specifically 
by decreasing atrophic markers and protein catabolism.  
While published research on M. oleifera may suggest it could be an effective ergogenic 
aid, a preliminary analysis on the basic adaptations to skeletal muscle structure, physiology, and 
performance, as well as potential alterations to metabolism is required. As such, we have 
designed unique experiments to evaluate the extent that M. oleifera supplementation affects 
energy metabolism and voluntary wheel running performance in mice. We hypothesized that M. 
oleifera would stimulate mitochondrial biogenesis by increasing gene expression of PGC-1α and 
PPARγ. We also hypothesized that increased mitochondrial content would increase succinate 
dehydrogenase (SHDB) and succinate-CoA ligase GDP/ADP-forming subunit alpha (SUCLG1), 
important enzymes in the oxidative phosphorylation pathway. Lastly, we hypothesize that M. 
oleifera would promote vascular health through increased expression of vascular endothelial 
growth factor (VEGF), a marker of angiogenesis, and endothelial nitric oxide (eNOS), a marker 
of vasodilation. Because compounds in M. oleifera have been shown to positively regulate 
protein balance [1, 5, 6, 8, 9, 17, 24, 25], we hypothesized that M. oleifera would increase fiber 
cross-sectional area (CSA) and alter expression levels of key factors implicated in protein 
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turnover such as atrogin-1 and myostatin. Together, if our hypotheses are supported, we will 
provide the initial data quantifying the impact of M. oleifera on muscle physiology in untrained 
subjects and establish a framework for future work to potentially identify the herb as an effective 
ergogenic aid. 
 
Materials & Methods 
Animals & Experimental Groups  
Male C57BL/6 mice (~6-8 wks of age) were randomly assigned to one of the following 
four experimental groups (N = 10/group): (1) Vehicle control + Sedentary (Vehicle + SED), (2) 
M. oleifera-supplemented + Sedentary (M. oleifera + SED), (3) Vehicle + volunteer wheel 
running (Vehicle + RUN), or (4) M. oleifera + RUN.  Effect size, power, and required sample 
size to attain a power of 0.8 at an alpha level of 0.05 have been calculated and suggested 10 
animals per experimental group was required.  Animals were housed in groups in a pathogen-
free animal facility under a 12-12h light-dark cycle.  Mice were fed normal chow ad libitum at 
8:00 am every day, allowed free access to drinking water, and provided with supplemental 
pellets (vehicle or M. oleifera) at 5pm every evening. These supplemental pellets were tracked 
the following morning to assess complete consumption. Animals were weighed daily as a 
surrogate marker of total dietary intake.  All experiments were approved by the Institutional 
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animal Care and Use Committee of Georgia State University and conformed to the National 
Institutes of Health (NIH) guidelines.  
 
Moringa Oleifera Formulation and Treatment Plan 
The ingredients of the M. oleifera pellet were as follows:  1) 2.0 g bleached & enriched 
cassava flour (Whole Foods, Atlanta, GA), organic peanut butter (a pinch for flavor) (Whole 
Foods, Atlanta, GA), 3.32 mL distilled water (Deer Park), and 0.10 g M. oleifera leaf powder 
(NC A & T University, Greensboro, NC), as previously described [26].  Pellets were formed 
manually, and all pellets were made the same size, containing approximately 0.10g of M. oleifera 
powder. Mice in the control-supplementation groups were fed pellets of similar size and 
contained the same ingredients, but that did not contain M. oleifera. Regardless of 
supplementation group, each cage of mice received one pellet per mouse (i.e., 5 pellets/cage) a 
day. The amounts of supplemental pellets consumed were tracked daily.  
Mice received experimental pellets for a total of 5 weeks (See Figure 6). After 3-weeks of 
supplementation, half of the mice from each group were singly housed in a cage that allowed 
free access to food and water. Their cages were provided with a voluntary running wheel (RUN) 
for the final 2-weeks of the study protocol. All groups continued their experimental diets during 
the volunteer wheel running experiments. At the end of the experimental protocol, mice were 
euthanized by CO2 asphyxiation followed by thoracotomy. Gastrocnemius, soleus, and plantaris 
muscles from one limb and the whole triceps surae group from the other limb were dissected and 
either snap frozen in liquid nitrogen or fixed in OCT compound immersed in melting isopentane 
for sectioning and subsequent histological analyses.  
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Volunteer Wheel Running 
 To assess the influence of M. oleifera on voluntary running activity, subgroups of vehicle 
supplemented, or M. oleifera-fed mice were maintained on their respective diet and provided free 
access to a running wheel (Super pet comfort wheel, 5.5” diameter, PetSmart, Inc., Phoenix, 
AZ).  This wheel was equipped with a cycle monitor (Velo 8 computer, CatEye Co. LTD, Osaka, 
Japan) and was used to calculate total distance run over a 12-hour period. To accomplish this, 
animals were placed in these modified cages at 7pm every evening and cycle monitors were 
checked at 7am the next morning. Mice were returned to group housing during the day and 
reintroduced into the running cages on this daily schedule for the next 14 days. 
 
Quantitative RT-PCR 
Total RNA was extracted from the gastrocnemius muscle using a RNeasy Mini Kit per 
manufacturer’s instructions (Qiagen, Germantown, MD).  Total RNA was then used to prepare 
cDNA using random primers and the iScript cDNA Synthesis kit (Biorad, Hercules, CA). 
Relative levels of mRNA were determined by real-time quantitative PCR using an Applied 
Biosystems cycler (Applied Biosystems, Foster City, CA) and the iQ SYBR Green Supermix 
(Biorad, Hercules, CA). Primers for beta-actin, PPARγ, PGC-1α, MYLPF, VEGFa, PGAM-1, 
PGK-1, SDHB, SUCLG1, AKT, atrogin-1, and myostatin (Integrated DNA Technologies, 
Coralville, IA) were used (Table 5). Briefly, cDNA samples were incubated at 95°C for 15 min, 
followed by 40 cycles of denaturation, annealing, and extensions at 95°C, 60°C, and 72°C, 
respectively. Fluorescence was recorded at the end of each annealing and extension step.  All 
reactions were performed in duplicate and the starting quantity of the gene of interest was 
50 
 
normalized to beta-actin rRNA for each sample.  The delta-delta Ct method was used to analyze 
alterations in gene expression and values are expressed as total mRNA expression. 
 
Muscle Histology (Fiber Cross-Sectional Area) 
 Triceps surae (TS) muscles were removed, embedded in OCT, and immediately frozen in 
isopentane cooled in liquid nitrogen.  Muscles were cut in 10 μm serial sections maintained at -
20°C using a cryostat (Leica CM1520, Buffalo Grove, IL). Sections were then processed for 
hematoxylin and eosin staining, dehydrated, mounted, and visualized at 20X with a Leica 
microscope.  Cross-sectional areas of approximately 100 fibers per muscle were calculated using 
ImageJ software (NIH, Bethesda, MD).  
 
Endothelial Nitric Oxide Synthase Immunoassay 
 eNOS protein content was examined in gastrocnemius skeletal muscle homogenates 
using a commercially available ELISA-based assay kit according to manufacturer’s instructions 
(Abcam, Cambridge, MA). Briefly, frozen gastrocnemius muscles were washed, minced, and 
homogenized in ice-cold PBS. Homogenates were centrifuged for 20 min at 18,000g and 
supernatants were used for quantification of total eNOS protein content.  
 
Statistical Analysis 
 An a priori power analysis was conducted using G*Power3.1.9.7 [27]  to test the 
difference between four independent group means using an ANOVA test, a medium effect size 
(d = 0.35), and an alpha level of 0.05.  Results indicated that a total sample of 40 mice with 4 
equal sized groups of N = 10 were required to achieve a power of 0.80.  Gene of interest (GOI) 
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mRNA expression were analyzed using a two-way ANOVA with factors of treatment (Vehicle 
and M. oleifera) and exercise (SED and RUN). Tukey correction factors were used to account for 
multiple pairwise comparisons. All data were analyzed and graphed using commercially 
available software (GraphPad Prism 8, San Diego, CA). Data are presented as mean + standard 
error. P < 0.05 was used for statistical significance.  
 
Results 
M. oleifera Improves Voluntary Wheel Running Performance 
 Over 14 days, the average daily voluntary wheel running distance was greater in M. 
oleifera mice compared to vehicle treated mice (4.21 + 0.16 vs. 3.63 +0.24 km, respectively; p = 
0.04) (Figure 7B).  Body weights and growth curves were similar between groups suggesting that 
5 weeks of supplementation, regardless of experimental diet, did not body size or weight (Figure 
7C).  
 
M. oleifera Promotes Mitochondrial Biogenesis & Oxidative Capacity 
We next examined the effects of M. oleifera and voluntary running activity on 
mitochondrial biogenesis.  There was not a statistically significant interaction between the effects 
of voluntary running activity and M. oleifera supplementation on PGC-1α expression.  M. 
oleifera + SED appeared to increase PGC-1α expression compared to vehicle + SED (3.22 + 
0.87 vs. 1.05 + 0.68 AU, respectively; p = 0.68) (Figure 8A).  Voluntary running (vehicle + 
RUN) increased the expression of PGC-1α compared to vehicle + SED (9.99 + 5.17 vs. 1.05 + 
0.68 AU, respectively; p = 0.11). 
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PPARγ, a key regulator of mitochondrial biogenesis, was increased in the M. oleifera + 
SED mice compared to the vehicle + SED mice (7.15 + 2.18 vs. 1.81 + 0.92 AU, respectively; p 
= 0.03) (Figure 8B). PPARγ mRNA expression was also increased in the vehicle + RUN group 
compared to the vehicle + SED group (14.41 + 6.81 vs. 1.81 + 0.92 AU, respectively; p = 0.01).  
Expression of PPARγ was also increased in the M. oleifera + RUN group compared to the 
vehicle + SED group (8.53 + 2.62 vs. 1.81 + 0.92 AU, respectively; p = 0.02). 
SDHB, an enzyme associated with Complex II of the Electron Transport Chain, appeared 
to increase in the M. oleifera + SED group compared to vehicle + SED (3.05 + 1.20 vs. 1.14 + 
0.25 AU, respectively; p = 0.36) (Figure 8C). SDHB was also increased in the vehicle + RUN 
group (4.67 + 2.01 vs. 1.14 + 0.25 AU, respectively; p = 0.09). Gene levels of SUCLG1, an 
enzyme that regulates the formation of succinate and ATP from succinyl CoA and ADP or GDP, 
were unchanged regardless of group (Figure 8D).  
 
M. oleifera Improves Vascular Health 
 Functional adaptations that improve running performance may also include angiogenesis 
and increased ability to deliver blood to working musculature while simultaneously removing 
metabolic byproducts. As such, we next investigated the effect of M. oleifera and exercise on 
markers of general vascular health by quantifying endothelial nitric oxide (eNOS) protein 
content and vascular endothelial growth factor (VEGF) gene levels. Protein content of eNOS was 
not altered in the M. oleifera + SED group compared to vehicle + SED group (3,793 + 410.6 vs. 
4,569 + 379.4 pg/mL, respectively; p = 0.68) (Figure 9A). M. oleifera + RUN mice did not have 
an affect on protein content compared to vehicle + SED group (3,149 + 451.9 vs. 4,569 + 379.4 
pg/mL, respectively; p = 0.19).  Furthermore, eNOS protein content remained unaffected in the 
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vehicle + RUN group compared to the vehicle + SED group (3,605 + 797.0 vs. 4,569 + 379.4 
pg/mL, respectively; p = 0.70).  
There was not a statistically significant interaction between the effects of voluntary 
running activity and M. oleifera supplementation on VEGF (Figure 9B).  Results indicate that 
VEGF appears to be increased in the M. oleifera + SED group compared to the vehicle + SED 
group (3.61 + 0.77 vs. 1.87 + 0.94 AU, respectively; p = 0.21).  M. oleifera + RUN also 
increased VEGF expression compared to the vehicle + SED group (3.91 + 1.41 vs. 1.87 + 0.94 
AU, respectively; p = 0.38).  VEGF was increased in the vehicle + RUN group compared to 
vehicle + SED group (6.33 + 2.55 vs. 1.87 + 0.94 AU, respectively; p = 0.22).    
 
Markers of Glycolysis and Fast-Twitch Fibers are Increased by M. oleifera 
Because M. oleifera improved voluntary wheel running distance, we next analyzed the 
impact M. oleifera had on key components of glycolysis.  PGAM-2, an enzyme that catalyzes the 
conversion of 3-phosphoglycerate to 2-phosphoglycerate in glycolysis appears to be increased in 
the M. oleifera + SED group compared to vehicle + sed group (4.39 + 1.02 vs. 2.10 + 1.09 AU, 
respectively; p = 0.07) (Figure 10A).  PGAM-2 was increased in the M. oleifera + RUN group 
compared to the vehicle + SED group (3.51 + 0.77 vs. 2.10 + 1.09 AU, respectively; p = 0.16). 
Vehicle + RUN mice also had an increase in PGAM-2 compared to the vehicle + SED group 
(6.58 + 2.76 vs. 2.10 + 1.09 AU, respectively; p = 0.10) (Figure 10A). 
PGK-1, which produces ATP and 3-phosphoglycerate was increased in the M. oleifera + 
SED group compared to vehicle + SED group (3.32 + 0.59 vs. 1.35 + 0.45 AU, respectively; p = 
0.04) (Figure 10B).  M. oleifera + RUN mice had an increase in PGK-1 compared to the vehicle 
+ SED mice (3.45 + 0.59 vs. 1.35 + 0.45 AU, respectively; p = 0.04). PGK-1 expression was also 
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increased in the vehicle + RUN group compared to the vehicle + SED group (5.83 + 2.64 vs. 
1.35 + 0.45 AU, respectively; p = 0.04). 
To examine the fiber-type profile in the gastrocnemius muscle in mice, we measured the 
mRNA expression of myosin regulatory light chain 2, skeletal muscle isoform (MYLPF). Results 
indicate that MYLPF is increased in the M. oleifera + SED group compared to the vehicle + SED 
group (5.70 + 0.88 vs. 1.67 + 0.77 AU, respectively; p < 0.01) (Figure 10C).  M. oleifera + RUN 
mice had an increase in MYLPF expression compared to vehicle + SED mice (7.50 + 2.63 vs. 
1.67 + 0.77 AU, respectively; p < 0.01).  MYLPF expression was increased in the vehicle + 
RUN group compared to the vehicle + SED group (5.73 + 1.96 vs. 1.67 + 0.77 AU, respectively; 
p = 0.02). 
 
Cross-Sectional Area is Augmented by M. oleifera 
Because M. oleifera increased voluntary running activity and altered metabolism, we next 
analyzed its potential role on triceps surae muscle fiber cross-sectional area (CSA).  Results 
indicate that CSA is greater in the M. oleifera + SED (253.2 + 15.04 μm2, p < 0.01) and M. 
oleifera + RUN (278.0 + 18.24 μm2, p < 0.01) groups compared to both the vehicle + RUN 
(174.9 + 22.11 μm2) and the vehicle + SED (172.2 + 6.82 μm2) groups (Figure 11A). 
Representative histological images are shown in Figure 11B.   
 
M. oleifera Decreases Markers of Atrophy 
We showed that M. oleifera was associated with larger fiber areas, therefore; we next 
analyzed key signaling components associated with protein synthesis and degradation. Protein 
kinase B (AKT) is a serine/threonine-specific protein kinase shown to play a vital role in many 
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cellular processes including regulation of skeletal muscle mass [28, 29].  Results indicate that 
AKT is increased in the vehicle + RUN group compared to the vehicle + SED group (5.40 + 1.14 
vs. 2.33 + 1.13 AU, respectively; p = 0.01).  There appears to be little to no change in AKT 
expression in the M. oleifera + SED (1.81 + 0.38 vs. 2.33 + 1.13 AU, respectively;  p = 0.94) and 
M. oleifera + RUN (2.18 + 0.63 vs. 2.33 + 1.13 AU, respectively; p = 0.84) groups compared to 
the vehicle + SED group (Figure 12A). 
In contrast, gene levels of atrogin-1, an E3 ligase associated with proteasomal 
degradation, had no statistically significant interaction between the effects of voluntary running 
activity and M. oleifera supplementation. Results indicate that atrogin-1 appears to be decreased 
in the M. oleifera + SED (0.83 + 0.18 vs. 1.21 + 0.33 AU, respectively; p = 0.48) and M. oleifera 
+ RUN (0.61 + 0.10 vs. 1.21 + 0.33 AU, respectively; p = 0.53) groups compared to the vehicle 
+ SED group (Figure 12B).   
  Furthermore, gene levels of myostatin, an inhibitor of muscle cell growth and 
differentiation, had a statistically significant interaction between the effects of voluntary running 
activity and M. oleifera supplementation.  Results indicate that myostatin expression appears to 
be unaffected in the M. oleifera + SED group compared to the vehicle + SED group (1.44 + 0.47 
vs. 3.31 + 2.07, respectively; p = 0.99).  Expression of myostatin in the M. oleifera + RUN group 
appears to be unchanged compared to the vehicle + SED group (1.63 + 0.37 vs. 3.31 + 2.07 AU, 
respectively; p = 0.98).  Myostatin expression appears to decrease in the vehicle + RUN group 
compared to the vehicle + SED group (0.50 + 0.32 vs. 3.31 + 2.07 AU, respectively; p = 0.11).  
Myostatin was also significantly less in the vehicle + RUN group compared to M. oleifera + 
RUN group (0.50 + 0.32 vs. 1.63 + 0.37 AU, respectively; p = 0.02) (Figure 12C). 
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DISCUSSION 
The main findings of this study suggest that M. oleifera may be a potential ergogenic aid 
and associated with: 1) increased endurance capacity by stimulating oxidative metabolism and 
mitochondrial biogenesis; 2) improved glycolytic metabolism; 3) enhanced vascular health; and 
4) decreased markers of protein degradation and increased fiber cross-sectional area.   To our 
knowledge, this is the first study that explored the impact of M. oleifera supplementation on 
skeletal muscle physiology, metabolism, and performance.    
 
M. oleifera Increases Oxidative Capacity 
Our data showed that after 5 weeks of M. oleifera supplementation several genes 
associated with oxidative phosphorylation (PGC-1α, PPARγ, SDHB, SUCLG1) and glycolysis 
(PGAM-2, PGK1) were increased.  Together, these improvements in energy metabolism likely 
influenced voluntary running distance during the final two weeks of supplementation.  In concert 
with our data, rats supplemented with M. oleifera for 4 weeks swam significantly longer 
compared to the vehicle group suggesting that M. oleifera may improve fatigue resistance [17].     
Because supplemented mice ran longer distances, we next examined the impact of M. 
oleifera on markers of mitochondrial biogenesis. Mitochondrial biogenesis involves the 
expansion of pre-existing mitochondria, a process dependent on the coordination of nuclear and 
mitochondrial-encoded gene expression [11, 30].  In response to exercise, PPARγ can be 
stimulated through the induction of PGC-1α, which when activated interacts with nuclear 
respiratory factors (NRFs) to promote mitochondrial biogenesis [31-34].    In concert with 
previous work, our data showed a significant increase in PGC-1α mRNA expression in mice with 
free access to a running wheel compared to sedentary controls. Interestingly, PGC-1α levels also 
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increased in mice supplemented with M. oleifera, suggesting that supplementation alone may be 
enough to drive mitochondrial biogenesis in the absence of increased physical activity. However, 
more research is required to truly define M. oleifera as a potential exercise mimetic.  
In addition to expanding the pool of mitochondria, increased voluntary activity also 
increases the content of oxidative enzymes in mitochondria [35, 36].  Accordingly, we measured 
gene expression levels of two proteins associated with oxidative phosphorylation, succinate 
dehydrogenase B (SDHB) and succinate CoA ligase 1 (SUCLG). SDHB is an enzyme complex 
involved in the Krebs cycle and electron transport chain that oxidizes succinate to fumarate [37, 
38].  In agreement with our results, exercise was shown to attenuate SDHB expression in mouse 
muscle after disuse [39].  Furthermore, exercise also increased citrate synthase, another enzyme 
active in the Krebs cycle [39].  As expected, we showed a significant increase in SDHB in the 
RUN group. Surprisingly, M. oleifera also increased SDHB mRNA expression in the absence of 
increased physical activity suggesting similar improvements to oxidative metabolism. Increases 
in citric acid cycle intermediates, like SUCLG and SDHB, have been associated with higher peak 
VO2 during acute exercise and faster marathon times [40-42].  Together, these genes are critical 
in maintaining oxidative metabolism during prolonged exercise [40-42].  As expected, our data 
showed that SUCLG1 mRNA was increased in the RUN and M. oleifera groups compared to the 
vehicle + SED group. This data suggests that M. oleifera may induce the same outcomes as 
running, possibly promoting oxidative metabolism.  
 
M. oleifera Promotes VEGF-Induced Oxidative Capacity 
With increased physical activity, vascular endothelial growth factor (VEGF) plays a 
central role in stimulating angiogenesis and increasing capillary density in skeletal muscle [11].  
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Furthermore, an increase in VEGF has been associated with both improved running speed and 
time to fatigue during endurance events [11].  In response to an 8-wk treadmill running program, 
VEGF-null skeletal myofibers of mice had diminished exercise capacity and decreases in 
markers of oxidative capacity (citrate synthase and beta-hydroxyacyl CoA dehydrogenase) [43].  
Moreover, maximal running speed was unchanged in the VEGF-null mice, but increased in the 
control mice [43].  Also, VEGF-null mice exhibited a 30% reduction in the time to exhaustion 
compared with untrained, VEGF-positive mice [43].  Most importantly, the VEGF-null mice did 
not improve endurance capacity, but the VEGF-positive mice increased the time to reach 
exhaustion by 99% [43] 
 Here, mice supplemented with M. oleifera had greater VEGF expression compared to 
vehicle control, which could explain, in part, why M. oleifera-supplemented mice voluntarily ran 
farther distances and had increased markers of oxidative phosphorylation. Multiple groups have 
reported that the formation of new capillaries within the muscle depends on dynamic cell to cell 
interactions [44-47].  Deletion of the VEGF gene from skeletal myofibers was shown to not 
affect capillarity in skeletal muscle [43, 44].  In VEGF-null gastrocnemius muscles fatigue onset 
was faster, there was no reduction in capillarity nor evidence of muscle contractile or metabolic 
dysfunction, which suggests a VEGF-dependent change in vascular reactivity and perfusion of 
the capillaries [44].  More importantly, the results suggest that VEGF may play a critical role in 
regulating oxygen delivery to the muscles [44].  These findings are in concert with our data.  
VEGF was increased with running, but more importantly M. oleifera was also able to induce 
VEGF expression. 
Skeletal muscle microcirculation is an important regulator of health and disease [48].  It 
also plays a critical role in exercise because it matches perfusion with metabolic demands [48].  
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A reduction in exercise-induced perfusion could be due to limited nitric oxide (NO) secondary to 
a decrease in VEGF levels in skeletal muscle [44].  Ideally then, VEGF-induced eNOS would 
increase NO release from endothelial cells [44, 49].  Although there were no changes in eNOS 
activity in the current work, running or M. oleifera supplementation may still increase 
vasodilation or blood flow through the release of prostaglandins, endothelium-derived 
hyperpolarizing factor, or AMPK [44, 50-52].   
    
Glycolytic Activity was Increased by M. oleifera-Supplementation 
Not only were oxidative related genes increased in the skeletal muscle of mice treated 
with M. oleifera, but enzymes associated with glycolysis were also induced, such as 
phosphoglycerate kinase-1 (PGK1) and phosphoglycerate mutase (PGAM2). During the first few 
minutes of exercise, these enzymes are important for the generation of ATP. Upregulation of 
genes involved in muscle glucose uptake and muscle glycolysis, including PGK1, suggests a 
compensatory response to maintain energy homeostasis and could lead to an increase in 
carbohydrate oxidation [53].  Healthy skeletal muscle has flexibility to switch between fatty acid 
and carbohydrate metabolism depending on substrate availability and exercise intensity [53, 54].  
Furthermore, athletes and sports nutritionists routinely attempt to improve sports performance by 
manipulating fuel metabolism in concert with exercise training [54].  Our data shows that M. 
oleifera has the potential to promote markers of glycolysis (PGK1 and PGAM2), as well as 
markers of oxidative metabolism (SUCLG1 and SDHB), which may suggest an increase in 
metabolic flexibility. 
Alternatively, changes in both oxidative and glycolytic markers may be because 
endurance exercise is more dependent on oxidative type muscle fibers (Type I and IIa) [55].  
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Furthermore, the recruitment of glycolytic muscle fibers (Type IIb and IIx) during endurance 
training may cause a “metabolic challenge” that leads to the induction of transient changes in 
gene expression [55].  These transient changes could contribute to alteration in muscle phenotype 
that could result in a more oxidative muscle [55].  When comparing our data to other studies, 
several variables may influence the gene induction response to exercise [55].  For example, we 
did not measure our gene response after one bout of exercise (acute), rather than analyzing 
changes following two weeks of voluntary wheel running activity. We also did not monitor the 
time of food intake (pre- or post-exercise). Feeding is an important consideration because fasting 
and feeding have both been shown to alter metabolic gene expression [55, 56].  For example, 
during short-term fasting, substrate utilization in skeletal muscle switches from carbohydrate to 
fat in order to conserve glucose [56].  After 20-h of fasting, transcription of pyruvate 
dehydrogenase was increased nine-fold compared to control, but was enhanced following 
refeeding [56].   
We analyzed whole gastrocnemius muscles for gene levels of fast skeletal myosin light 
chain (MYLPF). Running and M. oleifera increased the expression of MYLPF, suggesting an 
increase in fast fiber phenotype. Different types of exercise have been shown to induce 
differential expression of myosin protein isoforms in skeletal muscle [57, 58].  Most studies have 
focused on the composition of myosin heavy chain (MHC) because of its role in myosin ATPase 
activity and in the velocity of muscle fiber shortening [58, 59].  It is not well understood how 
exercise of different intensity and duration may affect the changes in the relative content of MLC 
isoforms and their distribution in different muscles [58].  However, it has been suggested that 
myosin light chains are necessary for full force development and shortening velocity [60, 61].  In 
support of our data,  5-weeks of endurance training has been shown to increase the content of 
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MYLPF in fast twitch muscles [58].  Furthermore, resistance training lead to an increase in 
MYLPF in the soleus muscle suggesting a transition toward a faster phenotype [58].  Based on 
these findings, our data may suggest that an increase of MYLPF could be aiding in force 
development and shortening velocity. However, due to the lack of specificity in isoform analysis, 
it is difficult to conclude the exact affect an increase in MLC-fast isoform may be having in the 
gastrocnemius muscle. Further studies will need to be performed to determine the effects M. 
oleifera may have on fiber-type phenotype. 
 
Protein Degradation is Decreased by M. oleifera-Supplementation 
While aerobic training and increased endurance-like activity are clearly associated with 
improvements in metabolism and refinement to substrate utilization, emerging research suggests 
these types of activities may promote skeletal muscle hypertrophy [20, 21]. To assess this, we 
analyzed key factors implicated in the regulation of muscle mass. Atrogin-1 is an E3 ligase 
involved in the ubiquitin proteasome pathway (UPP), which is responsible for most of the 
intracellular protein degradation in skeletal muscle [20].   Further, myostatin is also involved in 
the UPP, but is also a potent inhibitor of muscle growth due to its role in satellite regulation, 
muscle protein synthesis, and augmenting muscle protein breakdown [20].  Interestingly, both 
factors were decreased with M. oleifera supplementation. Together, this suggests that M. oleifera 
may increase net protein accretion by possibly decreasing the content of common catabolic 
factors. Similarly, chronic exercise training decreases atrogin-1 expression, which has 
preventative effects against muscle atrophy [62-64].  Both acute and repeated bouts of aerobic 
exercise have been shown to reduce myostatin mRNA expression, leading to increased muscle 
protein synthesis, myofiber and whole muscle hypertrophy, increased protein turnover, and 
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myocellular remodeling [65, 66].   In concert with these findings, we showed decreased atrogin-1 
and myostatin mRNA expression, as well as an increase in fiber CSA, suggesting that M. oleifera 
is associated with promoting hypertrophy and attenuating muscle atrophy.     
In summary, this is the first study to investigate the effects of M. oleifera on energy 
metabolism, vascular health, protein synthesis/degradation, and fiber-type profiles in mouse 
skeletal muscle.  This is evidenced by the facts that M. oleifera increased both glycolytic and 
oxidative metabolic genes, as well as increased markers of mitochondrial biogenesis and the 
MLC fast-type fiber phenotype gene, MYLPF. Further, M. oleifera decreased the expression of 
genes associated with protein degradation and promoted an increase in fiber CSA.  Although 
further studies are required, our data suggest that M. oleifera supplementation may confer 
benefits to basal muscle metabolism, increase the performance or duration of voluntary activity, 
and, therefore, be considered as a possible ergogenic aid.  
 
 
 
 
 
 
 
 
 
63 
 
References 
 
1. Azad, S.B., et al., Anti-hyperglycemic activity of &lt;em&gt; Moringa 
oleifera&lt;/em&gt; is partly mediated by carbohydrase inhibition and glucose-fiber 
binding. Bioscience Reports, 2017. 
2. Nwidu, L.E., E., Aprioku, JS, Siminialayi, I.; Carter, WG, In Vitro Anti-Cholinesterase 
and Antioxidant Activity of Extracts of Moringa oleifera Plants from Rivers State, Niger 
Delta, Nigeria. Medicines, 2018. 5(71). 
3. Paikra, B.D., HKJ; Gidwani, B., Phytochemistry and Pharmacology of Moringa oleifera 
Lam. Journal of Pharmacopuncture, 2017. 20(3): p. 194-200. 
4. Park, E.-J., et al., Inhibition of lipopolysaccharide-induced cyclooxygenase-2 and 
inducible nitric oxide synthase expression by 4-[(2'-O-acetyl-α-L-
rhamnosyloxy)benzyl]isothiocyanate from Moringa oleifera. Nutrition and cancer, 2011. 
63(6): p. 971-982. 
5. Jaja-Chimedza, A., et al., Biochemical characterization and anti-inflammatory properties 
of an isothiocyanate-enriched moringa (Moringa oleifera) seed extract. PloS one, 2017. 
12(8): p. e0182658-e0182658. 
6. Kou, X., et al., Nutraceutical or Pharmacological Potential of Moringa oleifera Lam. 
Nutrients, 2018. 10(3): p. 343. 
7. Sinha, M., et al., Leaf Extract of Moringa oleifera Prevents Ionizing Radiation-Induced 
Oxidative Stress in Mice. Journal of Medicinal Food, 2011. 14(10): p. 1167-1172. 
8. Jorge A. Sosa-Gutiérrez, M.A.V.-S., Tamara Y. Forbes-Hernández, Claudia I. Avitia-
Domínguez, Gonzalo G. Garcia-Vargas, José M. Salas-Pacheco, Oscar Flores-Herrera, 
Alfredo Téllez-Valencia, Maurizio Battino and Erick Sierra-Campos, Effects of Moringa 
oleifera Leaves Extract on High Glucose-Induced Metabolic Changes in HepG2 Cells. 
Biology, 2018. 7(37). 
9. Gupta, R., et al., Evaluation of antidiabetic and antioxidant activity of Moringa oleifera 
in experimental diabetes. Journal of Diabetes, 2012. 4(2): p. 164-171. 
64 
 
10. Ballmann, C., et al., Adult expression of PGC-1α and -1β in skeletal muscle is not 
required for endurance exercise-induced enhancement of exercise capacity. American 
journal of physiology. Endocrinology and metabolism, 2016. 311(6): p. E928-E938. 
11. Booth, F.W., et al., Chapter Six - Endurance Exercise and the Regulation of Skeletal 
Muscle Metabolism, in Progress in Molecular Biology and Translational Science, C. 
Bouchard, Editor. 2015, Academic Press. p. 129-151. 
12. Popov, D.V., et al., Effect of aerobic training on baseline expression of signaling and 
respiratory proteins in human skeletal muscle. Physiological reports, 2018. 6(17): p. 
e13868-e13868. 
13. Supruniuk, E., A. Mikłosz, and A. Chabowski, The Implication of PGC-1α on Fatty Acid 
Transport across Plasma and Mitochondrial Membranes in the Insulin Sensitive Tissues. 
Frontiers in physiology, 2017. 8: p. 923-923. 
14. Sellami, M., et al., Herbal medicine for sports: a review. Journal of the International 
Society of Sports Nutrition, 2018. 15: p. 14. 
15. Williams, M., Dietary Supplements and Sports Performance: Herbals. Journal of the 
International Society of Sports Nutrition, 2006. 3(1): p. 1-6. 
16. Henagan, T.M., et al., Dietary quercetin supplementation in mice increases skeletal 
muscle PGC1α expression, improves mitochondrial function and attenuates insulin 
resistance in a time-specific manner. PloS one, 2014. 9(2): p. e89365-e89365. 
17. Lamou, B., et al., Antioxidant and Antifatigue Properties of the Aqueous Extract of 
Moringa oleifera in Rats Subjected to Forced Swimming Endurance Test. Oxidative 
medicine and cellular longevity, 2016. 2016: p. 3517824-3517824. 
18. Muhammad, A.A., et al., Evaluation of wound healing properties of bioactive aqueous 
fraction from Moringa oleifera Lam on experimentally induced diabetic animal model. 
Drug design, development and therapy, 2016. 10: p. 1715-1730. 
19. Fernandes, E.E., et al., Probing Regenerative Potential of Moringa oleifera Aqueous 
Extracts Using In vitro Cellular Assays. Pharmacognosy research, 2016. 8(4): p. 231-237. 
20. Konopka, A.R. and M.P. Harber, Skeletal Muscle Hypertrophy after Aerobic Exercise 
Training. Exercise and sport sciences reviews, 2014. 42(2): p. 53-61. 
65 
 
21. Harber, M.P., et al., Protein synthesis and the expression of growth-related genes are 
altered by running in human vastus lateralis and soleus muscles. American Journal of 
Physiology-Regulatory, Integrative and Comparative Physiology, 2009. 296(3): p. R708-
R714. 
22. Bewaji, C. and M. Lambe, Protective role of Moringa oleifera leaf-based diet on protein- 
energy malnutrition induced skeletal muscle degeneration. International Journal of 
Scientific Reports, 2017. 3: p. 54. 
23. Le, N.H., et al., Quercetin Protects against Obesity-Induced Skeletal Muscle 
Inflammation and Atrophy. Mediators of Inflammation, 2014. 2014: p. 834294. 
24. Health Benefits of Moringa oleifera. Asian Pacific Journal of Cancer Prevention, 2014. 
15(20): p. 8571-8576. 
25. Atawodi, S.E., et al., Evaluation of the Polyphenol Content and Antioxidant Properties of 
Methanol Extracts of the Leaves, Stem, and Root Barks of Moringa oleifera Lam. Journal 
of Medicinal Food, 2010. 13(3): p. 710-716. 
26. Pilotos, J., et al., Moringa oleifera treatment increases Tbet expression in CD4(+) T cells 
and remediates immune defects of malnutrition in Plasmodium chabaudi-infected mice. 
Malaria journal, 2020. 19(1): p. 62-62. 
27. Faul, F., et al., G*Power 3: A flexible statistical power analysis program for the social, 
behavioral, and biomedical sciences. Behavior Research Methods, 2007. 39(2): p. 175-
191. 
28. Schiaffino, S. and C. Mammucari, Regulation of skeletal muscle growth by the IGF1-
Akt/PKB pathway: insights from genetic models. Skeletal muscle, 2011. 1(1): p. 4-4. 
29. Yoon, M.-S., mTOR as a Key Regulator in Maintaining Skeletal Muscle Mass. Frontiers 
in Physiology, 2017. 8(788). 
30. Arany, Z., PGC-1 coactivators and skeletal muscle adaptations in health and disease. 
Current Opinion in Genetics & Development, 2008. 18(5): p. 426-434. 
31. Puigserver, P. and B.M. Spiegelman, Peroxisome Proliferator-Activated Receptor-γ 
Coactivator 1α (PGC-1α): Transcriptional Coactivator and Metabolic Regulator. 
Endocrine Reviews, 2003. 24(1): p. 78-90. 
66 
 
32. Puigserver, P., et al., A Cold-Inducible Coactivator of Nuclear Receptors Linked to 
Adaptive Thermogenesis. Cell, 1998. 92(6): p. 829-839. 
33. Wu, Z., et al., Mechanisms Controlling Mitochondrial Biogenesis and Respiration 
through the Thermogenic Coactivator PGC-1. Cell, 1999. 98(1): p. 115-124. 
34. Miglio, G., et al., PPARγ stimulation promotes mitochondrial biogenesis and prevents 
glucose deprivation-induced neuronal cell loss. Neurochemistry International, 2009. 
55(7): p. 496-504. 
35. Terada, S., et al., Effects of low-intensity prolonged exercise on PGC-1 mRNA expression 
in rat epitrochlearis muscle. Biochemical and Biophysical Research Communications, 
2002. 296(2): p. 350-354. 
36. Holloszy, J.O., Biochemical Adaptations in Muscle: EFFECTS OF EXERCISE ON 
MITOCHONDRIAL OXYGEN UPTAKE AND RESPIRATORY ENZYME ACTIVITY IN 
SKELETAL MUSCLE. Journal of Biological Chemistry, 1967. 242(9): p. 2278-2282. 
37. Rutter, J., D.R. Winge, and J.D. Schiffman, Succinate dehydrogenase - Assembly, 
regulation and role in human disease. Mitochondrion, 2010. 10(4): p. 393-401. 
38. Punsoni, M., et al., Succinate Dehydrogenase B (SDHB) Immunohistochemistry for the 
Evaluation of Muscle Biopsies. Applied immunohistochemistry & molecular morphology 
: AIMM, 2017. 25(9): p. 645-650. 
39. Irimia, J.M., et al., Metabolic adaptations in skeletal muscle after 84 days of bed rest with 
and without concurrent flywheel resistance exercise. Journal of Applied Physiology, 
2016. 122(1): p. 96-103. 
40. Lewis, G.D., et al., Metabolic signatures of exercise in human plasma. Science 
translational medicine, 2010. 2(33): p. 33ra37-33ra37. 
41. Gibala, M.J., et al., Tricarboxylic acid cycle intermediate pool size and estimated cycle 
flux in human muscle during exercise. American Journal of Physiology-Endocrinology 
and Metabolism, 1998. 275(2): p. E235-E242. 
42. Gibala, M.J., et al., Anaplerotic processes in human skeletal muscle during brief dynamic 
exercise. The Journal of physiology, 1997. 502 ( Pt 3)(Pt 3): p. 703-713. 
67 
 
43. Delavar, H., et al., Skeletal myofiber VEGF is essential for the exercise training response 
in adult mice. American journal of physiology. Regulatory, integrative and comparative 
physiology, 2014. 306(8): p. R586-R595. 
44. Knapp, A.E., et al., Skeletal myofiber VEGF regulates contraction-induced perfusion and 
exercise capacity but not muscle capillarity in adult mice. American journal of 
physiology. Regulatory, integrative and comparative physiology, 2016. 311(1): p. R192-
R199. 
45. Chazaud, B., et al., Satellite cells attract monocytes and use macrophages as a support to 
escape apoptosis and enhance muscle growth. The Journal of cell biology, 2003. 163(5): 
p. 1133-1143. 
46. Abou-Khalil, R., R. Mounier, and B. Chazaud, Regulation of myogenic stem cell 
behaviour by vessel cells: The "ménage à trois" of satellite cells, periendothelial cells 
and endothelial cells. Cell Cycle, 2010. 9(5): p. 892-896. 
47. Olfert, I.M., et al., Myocyte vascular endothelial growth factor is required for exercise-
induced skeletal muscle angiogenesis. American journal of physiology. Regulatory, 
integrative and comparative physiology, 2010. 299(4): p. R1059-R1067. 
48. Cocks, M. and A.J.M. Wagenmakers, The effect of different training modes on skeletal 
muscle microvascular density and endothelial enzymes controlling NO availability. The 
Journal of physiology, 2016. 594(8): p. 2245-2257. 
49. Ahmad, S., et al., Direct Evidence for Endothelial Vascular Endothelial Growth Factor 
Receptor-1 Function in Nitric Oxide–Mediated Angiogenesis. Circulation Research, 
2006. 99(7): p. 715-722. 
50. Bradley Eloise, A., et al., Activation of AMP-Activated Protein Kinase by 5-
Aminoimidazole-4-Carboxamide-1-β-d-Ribofuranoside in the Muscle Microcirculation 
Increases Nitric Oxide Synthesis and Microvascular Perfusion. Arteriosclerosis, 
Thrombosis, and Vascular Biology, 2010. 30(6): p. 1137-1142. 
51. Huang, A., et al., In eNOS knockout mice skeletal muscle arteriolar dilation to 
acetylcholine is mediated by EDHF. American Journal of Physiology-Heart and 
Circulatory Physiology, 2000. 278(3): p. H762-H768. 
68 
 
52. Sun, D., et al., Enhanced Release of Prostaglandins Contributes to Flow-Induced 
Arteriolar Dilation in eNOS Knockout Mice. Circulation Research, 1999. 85(3): p. 288-
293. 
53. Peri-Okonny, P., et al., High-Phosphate Diet Induces Exercise Intolerance and Impairs 
Fatty Acid Metabolism in Mice. Circulation, 2019. 139(11): p. 1422-1434. 
54. Goodpaster, B.H. and L.M. Sparks, Metabolic Flexibility in Health and Disease. Cell 
metabolism, 2017. 25(5): p. 1027-1036. 
55. Yang, Y., et al., Time course of myogenic and metabolic gene expression in response to 
acute exercise in human skeletal muscle. Journal of Applied Physiology, 2005. 98(5): p. 
1745-1752. 
56. Pilegaard, H., B. Saltin, and P.D. Neufer, Effect of Short-Term Fasting and Refeeding on 
Transcriptional Regulation of Metabolic Genes in Human Skeletal Muscle. Diabetes, 
2003. 52(3): p. 657. 
57. Baldwin, K.M. and F. Haddad, Skeletal muscle plasticity: cellular and molecular 
responses to altered physical activity paradigms. Am J Phys Med Rehabil, 2002. 81(11 
Suppl): p. S40-51. 
58. Alev, K., Kaasik, P., Pehme, A., Aru, M., Parring, A., Elart, A., & Seene, T. , 
Physiological role of myosin light and heavy chain isoforms in fast- and slow-twitch 
muscles: effect of exercise. Biology of Sport, 2009. 26(3). 
59. Bottinelli, R., et al., Unloaded shortening velocity and myosin heavy chain and alkali 
light chain isoform composition in rat skeletal muscle fibres. J Physiol, 1994. 478 ( Pt 
2)(Pt 2): p. 341-9. 
60. Alev, K., Difference between myosin light and heavy chain isoforms patterns in fast- and 
slow-twitch skeletal muscle: effect of endurance training. 2005. 
61. Lowey, S. and K.M. Trybus, Role of skeletal and smooth muscle myosin light chains. 
Biophysical journal, 1995. 68(4 Suppl): p. 120S-127S. 
62. Al-Nassan, S., et al., Chronic Exercise Training Down-Regulates TNF-α and Atrogin-
1/MAFbx in Mouse Gastrocnemius Muscle Atrophy Induced by Hindlimb Unloading. 
Acta histochemica et cytochemica, 2012. 45(6): p. 343-349. 
69 
 
63. Morey-Holton, E.R. and R.K. Globus, Hindlimb unloading rodent model: technical 
aspects. Journal of Applied Physiology, 2002. 92(4): p. 1367-1377. 
64. Siu, P.M., E.E. Pistilli, and S.E. Alway, Age-dependent increase in oxidative stress in 
gastrocnemius muscle with unloading. Journal of applied physiology (Bethesda, Md. : 
1985), 2008. 105(6): p. 1695-1705. 
65. Harber, M.P., et al., Muscle protein synthesis and gene expression during recovery from 
aerobic exercise in the fasted and fed states. American Journal of Physiology-Regulatory, 
Integrative and Comparative Physiology, 2010. 299(5): p. R1254-R1262. 
66. Konopka, A.R., et al., Molecular adaptations to aerobic exercise training in skeletal 
muscle of older women. The journals of gerontology. Series A, Biological sciences and 
medical sciences, 2010. 65(11): p. 1201-1207. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 
 
APPENDICES 
 
 
Appendix A: Chapter 1 Tables and Figures 
 Type I Type IIa Type IIx Type IIb 
Contraction time Slow Moderately Fast Fast Very Fast 
Size of motor 
neuron Small Medium Large Very large 
Resistance to 
fatigue High Fairly High Intermediate Low 
Activity Used for Aerobic Long-term 
anaerobic 
Short-term 
anaerobic 
Short-term 
anaerobic 
Power Produced Low Medium High Very High 
Mitochondrial 
density High High Medium Low 
Capillary density High Intermediate Low Low 
Oxidative 
Capacity High High Intermediate Low 
Glycolytic 
Capacity Low High High High 
Myosin Heavy 
Chain (human 
genes) 
MYH7 MYH2 MYH1 MYH4 
 
 
 
 
 
 
 
 
 
Table 1. Skeletal Muscle Fiber Types.  A comparison of slow-twitch (type I) and fast-twitch (type II) 
skeletal muscle fibers. 
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Table 2. Extract Methods & Phytoconstituents of M. oleifera [69].  Various types of solvents have 
been used to extract a set of desired bioactive compounds for research and therapy, the most common 
include aqueous, ethanolic, and methanolic.  The type of phytochemical constituents extract from M. 
oleifera varies based on the part of the plant used. 
Plant Part Extract Phytoconstituents 
Potential Therapeutic 
& Ergogenic Effect 
Leaves 
Aqueous & 
alcoholic 
Niazirin and Niazirinin – nitrile 
glycosides,4-[(4’-O-acetylalpha-L-
rhamnosyloxy) benzyl isothiocyanate, 
Niaziminin A, Niaziminin B, three 
mustard oil glycosides, niaziminin, a 
thiocarbamate,4-alpha-1-
rhamnopyranosloxy)-
benzylglucosinolate, quercetin-3-O-
glucoside and quercetin-3-O-(6”-
Malonyl-glucoside), Niazimicin. 
 
Pyrrole alkaloid (pyrrolemarumine 400-
O-a-L-rhamnopyranoside) and 40-
hydroxypheylethenamide (marumoside 
A and B) 4 alpha and gamma-
tocopherol.2 
Hypotensive effect 
 
 
 
 
Seeds 
Aqueous & 
Hydro-alcoholic 
Methionine, cysteine, 4-(alpha-L-
rhamnopyranosyloxy) 
benzylglucosinolate, Moringine, 
benzylglucosinolate, niazimicin niazirin 
Metabolism & 
Angiogenesis 
Pods Hydro-alcoholic 
Isothiocyanate, nitrites, thiocarbamates, 
O-(1heptenyloxy) propyl undecanoate, 
O-ethyl-4(alpha-L-rhamnosyloxy) 
benzyl carbamate, methyl-p-
hydroxybenzoate, beta-sitosterol. 
Effects Nrf2 Activity 
Bark Alcoholic 
4-(alpha-L-rhamnopyranosyloxy) 
benzyl glucosinolate. 
Unknown 
Flowers Hydro-alcoholic 
D-glucose, quercetin, isoquercetin, 
kaempferol, kaempferitin and ascorbic 
acid, protein, D-mannose. 
Metabolism, Anti-
inflammatory, 
Antioxidant 
Root Alcoholic 
Moringine, moringinine, spirachin, 1,3-
dibenzyl urea, alpha-phellandrene, p-
cymene, Deoxy-niazimicine, 4-(alpha-
L-rhamnopyranosyloxy) 
benzylglucosinolate. 
Unknown 
Stem 
Aqueous and 
Hydro-alcoholic 
4-hydroxyl mullein, vanillin, 
octacosonoic acid, beta-sitosterone and 
beta-sitosterol. 
Anti-inflammatory, 
Antioxidant, Anti-
hyperlipidemia 
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Table 3. Pharmacological Activities of M. oleifera [69].  A representation of the pharmacological and 
medicinal uses of M. oleifera comparing different parts of the plant and extraction methods. 
Part of Plant Extract In-vitro/In-vivo Activity Standard Use 
Leaves & 
Roots 
Aqueous and 
alcoholic 
extracts 
In-vitro 
Anti-oxidant & 
radical 
scavenging 
activity 
- 
Leaves 
Methanolic 
extract 
In-vivo 
Antiepileptic 
activity & anti-
convulsant 
activity 
Pentylenetetrazole 
Leaves Aqueous extract In-vivo 
Anti-diabetic 
activity 
Streptozotocin 
Leaves 
Ethanolic 
extract 
In-vivo 
Cardiovascular 
activity/anti-
hypertensive 
- 
Roots Aqueous extract In-vivo 
Anti-fertility 
activity 
- 
Bark 
Aqueous and 
alcoholic 
extracts 
In-vitro 
Anti-urolithiatic 
activity 
Ethylene glycol 
Seed Kernel 
Alcoholic 
extract 
Human Study 
Anti-asthmatic 
activity 
- 
Leaves & 
Seeds 
Ethanolic 
Extract 
In-vivo 
Hepatoprotective 
activity 
- 
Leaves & 
Seeds 
Ethanolic 
Extracts 
In-vivo 
Anti-cancer 
activity 
- 
Root, Bark, 
leaves, flowers, 
seeds, stalks 
Methanolic & 
aqueous 
In-vitro 
Anti-
inflammatory 
activity 
Carrageen 
Leaves 
Macerated & 
infused aqueous 
extract, & 
ethanolic extract 
In-vitro 
Anthelminitic 
activity 
Piperazine citrate 
Leaves Aqueous extract In-vitro CNS activity Penicillin 
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Table 4.  Gene Sequences.  The gene name, primer name, forward & reverse sequence, and the signaling 
pathway the GOI is involved in. 
Gene Name 
Primer 
Name 
Forward Sequence Reverse Sequence 
Signaling 
Pathway 
Peroxisome 
proliferator-
activated receptor 
gamma 
PPARγ 
AGTACTGTCGGTT
TCGAAG 
GGGAAGGACTTTA
TGTATGAG 
Mitochondrial 
Biogenesis; 
Angiogenesis 
Peroxisome 
proliferator-
activated receptor 
gamma coactivator 
1-alpha 
PGC-1α 
TCCTCTTCAAGAT
CCTGTTAC 
CACATACAAGGG
AGAATTGC 
Mitochondrial 
Biogenesis; 
Angiogenesis 
Myosin light chain, 
phosphorylatable, 
fast skeletal muscle 
MYLPF 
CATCAACCTTCAC
TGTCTTCC 
ATGTTCTTGATCT
CCTCCTG 
Endurance 
Capacity (Fiber 
type 
“switching”) 
Vascular 
Endothelial Growth 
Factor 
VEGFa 
TAGAGTACATCTT
CAAGCCG 
TCTTTCTTTGGTCT
GCATTC 
Angiogenesis 
Kelch-like ECH-
associated protein-1 
KEAP1 
GGCTAATTGAGTT
CGCCTACAC 
GCAGTGTGACAGG
TTGAAGAA 
Mitochondrial 
Biogenesis 
Nuclear factor 
(erythroid-derived 
2)-like 2 
NRF-2 
AGAGCACTCTGTG
GAGCTTCC 
AGGCTGTACTGTA
TCCCCAGAA 
Mitochondrial 
Biogenesis 
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Figure 1. Molecular Signaling Pathway of Endurance Exercise-Induced Mitochondrial 
Biogenesis.  AMP-activated protein kinase (AMPK), Sirtuin (SIRT1), Peroxisome Proliferator-
Activated Receptor Gamma Coactivator 1-Alpha (PGC-1α), Nuclear Respiratory Factor (NRF), 
Peroxisome Proliferator-Activated Receptor Gamma (PPARγ), Transcription Factor A Mitochondrial 
(TFAM) 
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Figure 2. Mitophagy PINK1-PARKIN pathway of mitochondrial cells [1].  Fission and fusion of 
mitochondrial cells is crucial in maintaining healthy mitochondrial populations and cell function.  The 
most studied pathway of mitophagy involves PTEN-induced putative kinase protein 1 (PINK1) and 
PARKIN (component of a multiprotein E3 ubiquitin ligase complex).  These proteins relay the signals 
associated with damage to the induction of mitophagy.  As the mitochondrial inner membrane 
becomes depolarized, PINK1 stabilizes and recruits PARKIN from the cytosol onto the mitochondrial 
outer membrane.  This process leads to polyubiquitination of the mitochondrial outer membrane 
proteins and mitophagy. 
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Figure 3. Plant of M. oleifera.  Moringaceae is a tropical and subtropical plant species cultivated around 
the world, especially in sub-Himalayan regions of Northwest India.  It can grow to heights of up to 40 
feet, with a trunk diameter of 1.5 feet. 
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Figure 4. Plant parts of M. oleifera.  The flowers of M. oleifera contain yellowish-white petals, are 
fragrant, and asexual.  The fruit looks like giant bean-pods about 20-45 cm long.  The seeds are found 
within the fruit and are dark brown with a diameter around 1 cm.  The seeds are dispersed by wind and 
water.  The plant is trimmed and cut down annually to about 3-6 ft to increase its leaf biomass. 
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Figure 5. Proposed Experimental Design.  This shows the proposed schematic of a 5-week M. oleifera 
supplementation and 2-week exercise protocol. 
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Appendix B: Chapter 2 Tables and Figures 
 
Table 5.  Gene Sequences.  The gene name, primer name, forward & reverse sequence, and the signaling 
pathway the GOI is involved in. 
 
 
Gene Name 
Primer 
Name 
Forward Sequence Reverse Sequence Signaling Pathway 
Peroxisome 
proliferator-
activated 
receptor gamma 
PPARγ 
AGTACTGTCGGTTT
CGAAG 
GGGAAGGACTTTATG
TATGAG 
Mitochondrial 
Biogenesis; 
Angiogenesis 
Peroxisome 
proliferator-
activated 
receptor gamma 
coactivator 1-
alpha 
PGC-1α 
ATGTGTCGCCTTCT
TGCTCT 
ATCTACTGCCTGGGG
ACCTT 
Mitochondrial 
Biogenesis 
Myosin light 
chain, 
phosphorylatable
, fast skeletal 
muscle 
MYLPF 
CATCAACCTTCACT
GTCTTCC 
ATGTTCTTGATCTCCT
CCTG 
Endurance Capacity 
(Fiber-type 
“switching”) 
Vascular 
endothelial 
growth factor 
VEGFa 
TAGAGTACATCTTC
AAGCCG 
TCTTTCTTTGGTCTGC
ATTC 
Angiogenesis 
Phosphoglycerat
e mutase 1 
PGAM-1 
ACACCTCCATCAGC
AAGGAC 
GGGCTGCAATAAGCA
CTCTC 
Glycolysis 
Phosphoglycerat
e kinase 1 
PGK1 
GAAGGGAAGGGAA
AAGATGC 
TCAAAAATCCACCAG
CCTTC 
Glycolysis 
Succinyl-CoA 
Ligase (GDP-
forming) subunit 
alpha 
SUCLG1 
GGGATGACCGCAA
CAGTAGT 
AGGTACCCTGTTTGC
CTGTG 
Krebs Cycle 
Succinate 
dehydrogenase 
SDHB 
ACTGGTGGAACGG
AGACAAG 
GTTAAGCCAATGCTC
GCTTC 
Krebs Cycle 
Protein kinase B AKT 
CCCTTCTACAACCA
GGACCA 
ATACACATCCTGCCA
CACGA 
Protein 
Synthesis/Degradation 
Atrogin-1 Atrogin-1 
CTCTGCTGTGAGTG
CCACAT 
CAATGAGCCTGGGTA
CCACT 
Protein 
Synthesis/Degradation 
Myostatin Myostatin 
TGCAAAATTGGCTC
AAACAG 
GCAGTCAAGCCCAAA
GTCTC 
Protein 
Synthesis/Degradation 
80 
 
 
Figure 6. Experimental Design.  This shows the schematic of a 5-week M. oleifera supplementation and 
2-week exercise protocol. 
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Figure 7. M. oleifera improves voluntary wheel running performance.    (A) Representative images of 
normal mouse chow, vehicle pellets, and M. oleifera pellets.  (B) Voluntary wheel running distance was 
significantly longer in M. oleifera-treated mice compared to vehicle-treated mice.  Data are expressed as 
means + standard error.  (C) Body weights and growth curves were similar between groups suggesting 
that 5 weeks of supplementation, regardless of experimental diet, did not affect caloric intake nor appetite.  
*p < 0.05 compared with vehicle.   
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Figure 8. M. oleifera promotes oxidative capacity.  (A) Peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC-1α) appeared to increase in the M. oleifera-supplemented group but was 
significantly increased in the running group.  (B)  Peroxisome proliferator-activated receptor gamma 
(PPARγ) was significantly increased in the M. oleifera-supplemented, running, and M. oleifera + RUN 
groups.  (C) Succinate dehydrogenase-B (SDHB) mRNA expression appeared to be increased by M. 
oleifera-supplementation but was significantly greater in the RUN group.  (D) Succinyl-CoA Ligase 
(GDP-forming) subunit alpha (SUCLG1) expression appeared to be increased by M. oleifera 
supplementation & running.  *p < 0.05 compared with vehicle.  Data are expressed as means + standard 
error. 
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Figure 9. M. oleifera Improves Vascular Health.  (A)  Epithelial nitric oxide synthase (eNOS) was not 
affected by running nor by M. oleifera-supplementation.  (B)  Vascular endothelial growth factor (VEGF) 
was increased in M. oleifera-supplemented mice and in the running group.  Data are expressed as means + 
standard error. 
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Figure 10. M. oleifera Promotes Glycolytic Activity.  (A)  Phosphoglycerate mutase (PGAM-2) 
appeared to be increased in the running and M. oleifera-supplemented groups.  (B)  Phosphoglycerate 
kinase-1 (PGK-1) was significantly increased in M. oleifera-supplemented mice and in the running group.  
(C) Myosin regulatory light chain 2, skeletal muscle isoform (MYLPF) was significantly increased in M. 
oleifera-supplemented mice and in the running group.  *p < 0.05 compared with vehicle.  Data are 
expressed as means + standard error. 
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Figure 11. Cross-Sectional Area is Augmented by M. oleifera-Supplementation.  (A)  Average area of 
fiber diameter (µ2) was significantly greater in the gastrocnemius muscles of mice supplemented with M. 
oleifera.  (B)  Representative histological images of hematoxylin and eosin stained gastrocnemius 
muscles (20x).  Magnification bar is 100 μm.  *p < 0.05 compared with vehicle.  Data are expressed as 
means + standard error. 
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Figure 12. M. oleifera Decreases Atrophic-Related Gene Expression.  (A)  The mRNA expression of 
protein kinase B (AKT) was significantly greater in the RUN group but was not affected by M. oleifera-
supplementation.  (B)  Atrogin-1 mRNA expression appeared to be decreased in mice supplemented with 
M. oleifera.  (C) Myostatin mRNA expression appeared to be down regulated in mice supplemented with 
M. oleifera compared to vehicle, but it was significantly decreased in the vehicle + RUN group compared 
to the M. oleifera + RUN group.  *p < 0.05 compared with vehicle.  Data are expressed as means + 
standard error. 
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MEMORANDUM 
  
To:  Jeffrey Otis 
  Kinesiology & Health 
  
FROM:  Dr. Richard Plemper, Chair 
  Institutional Animal Care and Use Committee 
RE: Protocol Number: A19043 
Protocol Title: Moringa Oliefera and Skeletal Muscle Health 
Animal Type and Quantity: Mus musculus (48) 
Approval Period: 05/07/2019 - 03/22/2022 
   
Your protocol referenced above was approved by the Georgia State University’s Animal Care and Use 
Committee on May 07, 2019.  This approval is for the following amendment to your previously approved 
protocol: 
  
Add Desiree Wanders as Approved Personnel 
  
This approval will remain in effect for the three-year proposal period.   
  
Any additional changes to the current protocol must be approved before implementation.  Submit any 
additional changes on the Amendment Form. 
  
Any unexpected adverse effects of the experiments described in this protocol must be reported to the 
chair of the IACUC immediately. 
  
Protocol approval does not guarantee animal housing space.  Please contact Dean Blake to request 
animal housing space.  Note:  When ordering animals please refer to your full protocol number A19043. 
  
Georgia State University has an Animal Welfare Assurance on file with the Office of Laboratory Animal 
Welfare (OLAW).  The Assurance number is D16-00527 (A3914-01). 
  
Richard K. Plemper, Ph.D. 
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8.2  Rationale and Significance (Why are you doing it?)
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9.0  
USDA Animal Use Category Classification
USDA Classifications and Examples of Pain Categories:
 Animals being bred, conditioned, or held for use in teaching, testing, experiments, Classification B:
research, or surgery, but not yet used for such purposes.
Examples:
Breeding colonies - Includes parents and offspring.
Animals held under proper captive conditions or wild animals that are being observed.
 
 Animals upon which teaching, research, experiments, or tests will be conducted Classification C:
involving no pain, distress, or use of pain-relieving drugs.
Examples:
Procedures performed correctly by trained personnel such as the administration of electrolytes
/fluids, administration of oral medication, blood collection from a common peripheral vein per 
standard veterinary practice or catheterization of same, standard radiography, parenteral 
injections of non-irritating substances.
Euthanasia performed in accordance with the recommendations of the most recent AVMA Panel 
, utilizing procedures that produce rapid unconsciousness and subsequent humane on Euthanasia
death.
Manual restraint that is no longer than would be required for a simple exam; short period of chair 
restraint for an adapted nonhuman primate.
 
 Animals upon which experiments, teaching, research, surgery, or tests will be conducted Classification D:
involving accompanying pain or distress or leading to illness to the animals and for which appropriate 
anesthetic, analgesic, or tranquilizing drugs will be used.
Examples:
Surgical procedures conducted by trained personnel in accordance with standard veterinary 
practice such as biopsies, gonadectomy, exposure of blood vessels, chronic catheter implantation, 
laparotomy or laparoscopy.
Blood collection by more invasive routes such as intracardiac or periorbital collection from species 
without a true orbital sinus such as rats and guinea pigs.
Administration of drugs, chemicals, toxins, or organisms that would be expected to produce pain 
or distress but which will be alleviated by analgesics.
 
 Animals upon which teaching, experiments, research, surgery, or tests will be conducted Classification E:
involving accompanying pain or distress or leading to illness to the animals and for which the use of 
appropriate anesthetic, analgesic, or tranquilizing drugs will adversely affect the procedures, results, or 
interpretation of the teaching, research, experiments, surgery, or tests.
Examples:
Procedures producing pain or distress unrelieved by analgesics such as toxicity studies, microbial 
virulence testing, radiation sickness, and research on stress, shock, or pain.
Surgical and postsurgical sequella from invasion of body cavities, orthopedic procedures, dentistry 
or other hard or soft tissue damage that produces unrelieved pain or distress.
Negative conditioning via electric shocks that would cause pain in humans.
Chairing of nonhuman primates not conditioned to the procedure for the time period used.
 
9.1  Selection of Pain Category
Please classify the project according to the level of perceived pain / stress / distress experienced by the animal(s). Animals 
must be claimed under the highest class involved at any point prior to euthanasia or release. Highest Pain Category within 
this protocol:(enter B, C, D, or E)
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9.4  Will any adverse effects or overt signs of illness be expected?
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9.5  Monitoring of Animal Pain and Comfort Levels
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10.0  
Justification for Animal Use and Species Selection
10.1  Animal characteristics
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10.2  This species has been selected because ( )check all that apply
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10.3  Please justify why animals must be used instead of using methodology that does not require vertebrate animal use (e.g., cell 
culture, computer modeling).
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11.0  
Justification for the number of animals that will be used
11.1  Over a period of three (3) years what is the total number of animals you would like to use?

11.2  Group sizes are expected to represent the minimum number of animals that are needed to achieve the scientific or 
instructional objectives. Please  all the methods used to determine these numbers. indicate
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11.3  Using the specifics of your experimental plan demonstrate how the numbers of animals required to achieve your scientific objectives 
for this project were calculated. Include details of numbers of animals per group, control groups, treatment groups, pilot studies, and 
potential experimental failure. Information MUST be provided in the form of a table (recommend attaching a file for multiple tables).
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12.0  
Animal Use Narrative
12.1  Please describe in narrative form all experimental or instructional procedures to be performed on the animals. Please note 
that it is not necessary to provide the details already provided elsewhere in the protocol (e.g. procedure descriptions, 
volumes of blood collected, dosages, routes of administration, use of aseptic procedures, etc.). However, it is important that 
one is able to ascertain what procedure or set of procedures is conducted on each group of animals. Include the time frames 
and intervals between procedures and describe the procedures in the order they will be performed.
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13.0  
Procedures
13.1  Will any substance such as Complete Freund’s Adjuvant or other adjuvants be injected which could cause chronic inflammation and
/or pain?
/4B
&>
13.2  Will your study involve prolonged physical restraint (greater or equal to 30 mins)?
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13.3  Will you perform surgical procedures under this protocol on animals?
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13.4  Please select the non-surgical procedures that will be used under this protocol:
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14.0  
Method(s) of Euthanasia
14.1  Describe in detail all the methods of euthanasia (if any) you will use. If the method involves the use of pharmaceuticals, 
please specify agent, dose, and route of administration.
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14.2  How will death be confirmed?
.8C70=8<0;B4DC70=8I43F8C7'>A!B>5;DA0=4	0B42>=30AH?7HB820;<4C7>3F8;;144<?;>H4346
24AE820;38B;>20C8>=	18;0C4A0;C7>A02>C><H	<09>AE4BB4;CA0=B42C8>=
=8<0;B4DC70=8I43F8C702><<4A280;4DC70=0B80B>;DC8>=B>38D<?4=C>10A18C0;?A>3D2C	=>
B42>=30AH?7HB820;<4C7>38B=443431DCC740=8<0;F8;;142742:43C>0BBDA4C74A48B70B144=0
24BB0C8>=>5C74740AC140C0BF4;;0BA4B?8A0C8>=B
'C74A?;40B48=3820C48=C4GC1>G14;>F
14.3  How will remains be disposed?
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15.0  
Substance Administration
15.1  Please indicate below what type of substance(s) you will be using on your protocol:
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I will ensure that all relevant lab personnel have read and will adhere to the standards specified in the B:3</.
+>/<3+6="963-C8/=>2/>3-
8+61/=3+9<7?6+<C"963-C3B3819<36?>3818/=>2/>3-

8+61/=3-1/8>="963-C	
/4B
&>
15.3  Non-Pharmaceutical Substance Description
If anesthetics, analgesics, or any other substances are administered during the conduct of a procedure, please describe:
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As applicable, I will ensure that all relevant lab personnel have read and will adhere to the standards specified in the GSU 
.IACUC Policy on the Use of Non-Pharmaceutical Grade Substances (Topical or Oral Use)
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16.0  
Non-duplication of Research
 
16.1  Consideration of non-duplication of research
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17.0  
Personnel and Their Experience and Training
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18.0  
Hazard Use
 
All Hazardous Materials used must be identified.
For more information on the Biosafety program please click: GSU Biosafety Program
For more information on the Radiation Safety program please click: GSU Radiation Safety
For more information on GSU Lab Safety and Hazard Communication please click: https://ursa.
research.gsu.edu/laboratory-ennvironmental-safety/
For more information on GSU Chemical Safety please click: https://ursa.research.gsu.edu/chemical-
safety/
18.1  Are you working with infectious agents and/or biologically-derived toxins?
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18.2  Does the project use any recombinant DNA (i.e. cloning/expression systems, viral vectors, etc.) material in animals?
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18.3  Will any carcinogenic or toxic compounds be used in animals?
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18.4  Will any radioactive compounds be administered to the animals or will the study otherwise involve a radiation device (e.g. 
an x-irradiator for total body irradiation, an x-ray machine, etc.)?
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18.5  Will Controlled Substances be used?
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19.0  
Animal Housing and Husbandry
19.1  Do the animals require housing other than standard caging/bedding or tanks/water?
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19.2  Will animals be housed singly?
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19.3  Do the animals require special care?
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19.4  Do the animals require a diet other than the standard diet for this species used at GSU?
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19.5  Will food and/or fluid restriction(s) be necessary?
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19.6  Will animals remain outside the IACUC approved Animal Housing Area for more than 12 hours?
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19.7  Will animals undergo experimental manipulations outside the IACUC approved Animal Housing Area?
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19.8  Can animals be provided environmental enrichment?
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19.10  Does this protocol involve the use of any rodent species?
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20.0  
PHS Policy
20.1  The PHS Policy on Humane Care and Use of Laboratory Animals and Animal Welfare Regulations define the 
responsibilities of the IACUC regarding review and approval of animal activities.
Changes that may be handled administratively without IACUC-approved policies, consultations, or notifications include:
correction of typographical errors
correction of grammar
contact information updates
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